

Original Article

Light Alcohol Drinking and Risk of Cancer: A Meta-analysis of Cohort Studies

Yoon-Jung Choi, MD¹, Seung-Kwon Myung, MD, PhD^{1,2,3}, Ji-Ho Lee, MD¹

¹Department of Family Medicine and Center for Cancer Prevention and Detection, Hospital, National Cancer Center, Goyang, ²Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, ³Cancer Epidemiology Branch, Division of Cancer Epidemiology and Prevention, Research Institute, National Cancer Center, Goyang, Korea

Running title: Light alcohol drinking and cancer

Correspondence: Seung-Kwon Myung, MD, PhD

Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea

Tel: 82-31-920-0479 Fax: 82-31-920-2606 E-mail: msk@ncc.re.kr

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as an 'Accepted Article', doi:10.4143/crt.2017.094

Abstract

Purpose

To determine whether light alcohol drinking increases the risk of cancer by using a meta-analysis of cohort studies because the newly revised 2015 European Code against Cancer 4th edition on alcohol and cancer was based on critical flaws in the interpretation and citation of the previous meta-analyses.

Materials and Methods

PubMed and EMBASE were searched in April, 2016. Two authors independently reviewed and selected cohort studies on the association between very light (≤ 0.5 drink/day), light (≤ 1 drink/day), or moderate drinking (1-2 drinks/day) and the risk of cancer incidence and mortality. A pooled relative risk with its 95% confidence interval was calculated by a random-effects meta-analysis. Main outcome measures were cancer incidence and mortality.

Results

A total of 60 cohort studies from 135 articles were included in the final analysis. Very light drinking or light drinking was not associated with the incidence of most cancers except for female breast cancer in women and male colorectal cancer. Conversely, light drinking was associated with a decreased incidence of both female and male lung cancer significantly and both female and male thyroid cancer marginally significantly. Moderate drinking significantly increased the incidence of male colorectal cancer and female breast cancer, whereas it decreased the incidence of both female and male hematologic malignancy.

Conclusion

We found that very light or light alcohol drinking was not associated with the risk of most of the common cancers except for the mild increase in the incidence of breast cancer in women and colorectal cancer in men.

Key words Alcohols, Neoplasms, Cohort studies, Meta-analysis

Introduction

Alcohol is classified as Group 1 carcinogen by the International Agency for Research on Cancer (IARC), which category is used when there is sufficient evidence of carcinogenicity in humans [1]. However, it was usually excessive alcohol drinking that was condemned for causing cancer, and light or moderate alcohol consumption has been conceived as acceptable or even encouraged because of its known benefits in preventing cardiovascular diseases. Previously in 2003, the third edition of European Code against Cancer (ECAC) recommended that "If you drink alcohol, whether beer, wine or spirits, moderate your consumption to two drinks per day if you are a man or one drink per day if you are a woman." [2,3]. In 2015, the IARC published an article involving the newly revised ECAC 4th edition on alcohol drinking and cancer, which recommends "If you drink alcohol of any type, limit your drinking. Not drinking is better for cancer prevention." [4].

Since the publication of the ECAC 4th edition, however, Prof. Myung, the corresponding author of this paper claimed in the letter to the editor that the new ECAC on alcohol should be corrected because there were considerable critical flaws in the interpretation and citation of the existing observational epidemiological studies and meta-analyses on the association between light alcohol drinking (≤ 1 drink/day or 12.5g/day) and the risk of cancer [5]. He criticized that the authors of the ECAC 4th edition did not consider the difference in findings between case-control studies and cohort studies: there was no significant association between light alcohol drinking and the risk of oropharyngeal cancer and colon cancer in the meta-analysis of cohort studies, whereas light alcohol drinking increased the risk of oropharyngeal cancer and colorectal cancer in the meta-analysis of case-control studies. Moreover, they incorrectly used the data for 'moderate drinking (2-3 drinks/day)' or just 'drinking' instead of 'light drinking' in some analyses. Prof. Myung also published another letter to the editor [6]

criticizing erroneous conclusions about the association between light alcohol drinking and the risk of cancer in Bagnardi *et al*'s meta-analysis [7], which concluded that light alcohol drinking increased the risk of cancer of oropharynx, oesophagus, and female breast and consequently contributed to the newly revised ECAC. Similarly, he pointed out that in Bagnardi *et al*'s meta-analysis, except for female breast cancer, the meta-analysis of cohort studies did not show any significant association between light alcohol drinking and the risk of cancer of oropharynx, larynx, oesophagus, colorectum, and liver, whereas the meta-analysis of case-control studies showed a significant positive association between light drinking and cancer of oropharynx and oesophagus [6]. In summary, regarding the association between light alcohol drinking and the risk of cancer, the previous meta-analysis and the new ECAC 4th edition led to erroneous conclusions and incorrect recommendations due to the wrong interpretation and citations of the existing observational epidemiological studies.

Thus, we performed a comprehensive meta-analysis of cohort studies on this topic in order to investigate whether or not very light or light alcohol drinking as well as moderate alcohol drinking increased the risk of cancer.

Methods

Search strategy

We searched PubMed and EMBASE in March 31, 2016 using keywords "alcohol consumption," "alcohol intake," "cancer," and "cohort study." We also reviewed the bibliographies of relevant articles to find additional studies.

Selection criteria

We included prospective or retrospective cohort studies reporting a multivariate adjusted

relative risk (RR) with its 95% confidence interval (CI) for the association between light alcohol drinking (≤ 1 drink/day) and/or moderate alcohol drinking (1-2 drinks/day) and the risk of cancer. The current analysis involved general healthy populations. Thus, we excluded studies involving patients with underlying cancer and populations at high risk for a specific cancer such as patients with liver cirrhosis or hepatitis B virus carriers at high risk for liver cancer and those with Barrett's esophagus at high risk for esophageal cancer. Also, we excluded 1) studies that adjusted for only age and/or sex in the multivariate analysis, 2) studies that used 0-2 drink/day as criteria for light alcohol drinking instead of 1-2drinks/day, and 3) studies that used 0.5 drink/day or more as a reference value.

Selection of relevant studies

Two authors (YJ Choi and JH Lee) of the current study independently selected relevant studies in the first screening process. Any disagreements were solved by discussion and in consult with a third author (SK Myung). If data were duplicated or shared in more than one article, we included the more comprehensive or more recently published article for the analysis.

Main analysis and subgroup analysis

We investigated the risk of each type of cancer in both incidence and mortality according to different levels of alcohol drinking: very light drinking (≤ 0.5 drink/day), light drinking (≤ 1 drink/day), and moderate drinking (1-2 drinks/day). In general, one drink of alcohol corresponds to one unit of alcohol (12.5g) which is contained in one glass of beer (355mL), one glass of wine, and a single shot of hard liquor. However, since a number of studies used up to 15 g/day as 1 drink/day, we accepted up to 15 g as 1 drink of alcohol. 7 drinks/week,

105 g/week, 30 drinks/month, and 15 ounce/month were considered equivalent to 1 drink/day or light drinking. Likewise, 3.5 drink/week, 52.5 g/week, 15 drinks/month, and 7.5 ounce/month were considered as 0.5 drink/day or very light drinking. Also, 15-30 g/day, 7-14 drinks/week, 105-210 g/week, 30-60 drinks/month, and 15-30 ounce/month were categorized to 1 to 2 drinks/day or moderate drinking. We chose the upper limit of the range of drinking to categorize levels of drinking: 5-15g/day of drinking was considered as light drinking; if the upper limit exceeded 15g/day, then it was categorized as moderate drinking. We performed the subgroup meta-analysis by type of cancer and gender.

Assessment of methodological quality of included studies

The methodological quality of the included studies was based on the Newcastle-Ottawa Scale (NOS) [8] (Supplementary S3 and S4). This scale has a star system (range, 0-9 stars) for the assessment. Standard criteria for high quality have not been established. Regarding outcome assessment, a star was given for a follow-up period of ≥ 5 years and a follow-up rate of $\geq 90\%$.

Statistical analysis

We used the adjusted RR with its 95% CI in order to compute a pooled RR with its 95% CI. Heterogeneity was assessed by Higgins I^2 , which is the percentage of total variation across the studies as follows:

$$I^2 = 100\% \times (Q - df) / Q$$

where df refers to degrees of freedom, and Q refers to Cochran's heterogeneity statistics [9]. An I^2 value lies between 0% (no observed heterogeneity) and 100% (maximal heterogeneity). In general, an I^2 greater than 50% is considered to have substantial heterogeneity. We used a

random-effects model meta-analysis based on the DerSimonian and Laird method because most cohort studies were conducted in the different populations [10, 11]. A STATA version 13.1 software (StataCorp LP, College Station, TX, USA) was used for statistical analysis.

Results

Selection of relevant studies

Figure 1 shows a flow diagram of how we selected relevant studies. We identified a total of 4721 articles consisting of 3264 articles from PubMed and 1457 articles from EMBASE. We excluded 787 duplicate articles and 3503 articles that did not meet the selection criteria after reviewing 3934 articles based on titles and abstracts. After reviewing the full text of the remaining 431 articles along with additional 65 articles newly located from relevant bibliographies, 361 articles were excluded because of studies sharing an identical population ($n = 27$), insufficient data ($n = 94$), studies with no available data for outcome measures ($n = 53$), review or meta-analysis ($n = 18$), case-studies or other study designs ($n = 23$), and no relevant studies ($n = 146$). From a total of 135 articles, 60 cohort studies were included in the final analysis (References of 135 articles are presented in eReferences available on-line).

Characteristics of studies included in the final analysis

All the 60 cohort studies included in the final analysis involved a total of 9,428,076 participants (5,478,133 women and 3,949,943 men). As an outcome measure, all studies reported cancer incidence, and 14 studies reported cancer mortality. The number of studies according to cancer organ site were as follows (incidence, mortality): oral cavity and oropharynx ($n = 5$, $n = 2$), oesophagus (squamous cell carcinoma) ($n = 2$), oesophagus (adenocarcinoma) and cardia ($n = 3$), stomach ($n = 9$, $n = 2$), colorectum ($n = 16$, $n = 5$), liver ($n =$

2, n = 2), pancreas (n = 5, n = 4), lung cancer (n = 10, n = 5), female breast (n = 27, n = 7), endometrium (n = 9), ovary (n = 5), prostate (n = 14, n = 4), kidney (n = 7, n = 1), bladder (n = 4), hematologic malignancies (n = 8, n = 2), and skin (malignant melanoma) (n = 3) (Table 1).

Studies were conducted in North America (n = 30, n = 10), Europe (n = 21), and Asia (n = 9, n = 4) (Table 1). General characteristics of the studies included in the final analysis by cancer incidence and mortality are presented in supplementary S1 and S2 Tables available on-line.

Methodological quality of studies

Supplementary S3 and S4 Tables shows the methodological quality of the studies included in the analysis. The range of scores was 5 to 9 for cancer incidence and 6-8 for cancer mortality. The mean score was 6.8 for cancer incidence studies (n = 121) and 6.9 for cancer mortality studies (n = 14).

Very light alcohol drinking and the risk of cancer

Incidence

Table 2 shows the associations between cancer incidence and very light, light, and moderate alcohol drinking. Overall very light drinking (≤ 0.5 drink/day) was not associated with the incidence of most cancers. However, very light drinking was significantly associated with a decreased incidence of both female and male lung cancer (RR, 0.89; 95% CI, 0.84-0.93; $I^2 = 3\%$; n = 3), female lung cancer (RR, 0.82; 95% CI, 0.70-0.95; $I^2 = 12.9\%$; n = 2), whereas it increased the incidence of female breast cancer (RR, 1.04; 95% CI, 1.01-1.07; $I^2 = 3.7\%$; n = 20). There was no significant association between very light drinking and the incidence of head and neck cancer, oesophageal cancer, stomach cancer, colorectal cancer, pancreatic cancer, endometrial cancer, ovary cancer, prostate cancer, kidney cancer, bladder cancer,

thyroid cancer, and hematologic malignancy.

Mortality

Table 3 shows the associations between cancer mortality and very light, light, and moderate alcohol drinking. Very light drinking reduced the mortality of both female and male lung cancer (RR, 0.81; 95% CI, 0.69-0.94; $I^2 = 0.0\%$; $n = 2$), female lung cancer (RR, 0.70; 95% CI, 0.56-0.89; $n = 1$) and female breast cancer (RR, 0.79; 95% CI, 0.64-0.97; $I^2 = 0.0\%$; $n = 2$). There was no significant association between very light drinking and the mortality of colorectal cancer, gall bladder cancer, prostate cancer, and hematologic malignancy.

Light alcohol drinking and the risk of cancer

Incidence

As shown in Table 2, similar to the findings of very light alcohol drinking, overall light drinking (≤ 1 drink/day) was not associated with the incidence of most cancers. However, light drinking was significantly associated with a decreased incidence of both female and male lung cancer (RR, 0.91; 95% CI, 0.90-0.94; $I^2 = 0.0\%$; $n = 10$), male lung cancer (RR, 0.91; 95% CI, 0.90-0.95; $I^2 = 0.0\%$; $n = 3$), and female lung cancer (RR, 0.90; 95% CI, 0.87-0.94; $I^2 = 0.0\%$; $n = 4$), whereas it increased the incidence of female breast cancer (RR, 1.09; 95% CI, 1.06-1.12; $I^2 = 32.8\%$; $n = 25$; Figure 2), both female and male colorectal cancer (RR, 1.04; 95% CI, 1.04-1.06; $I^2 = 0.0\%$; $n = 14$), male colorectal cancer (RR, 1.06; 95% CI, 1.01-1.11; $I^2 = 0.0\%$; $n = 6$; Figure 3), and both female and male malignant melanoma (RR, 1.44; 95% CI, 1.18-1.76; $I^2 = 0.0\%$; $n = 3$). In the subgroup meta-analysis by type of male colorectal cancer, light drinking was not associated with the incidence of either colon cancer (RR, 1.02; 95% CI, 0.87-1.21; $I^2 = 0.0\%$; $n = 5$) or rectal cancer (RR, 1.07; 95% CI, 0.69-1.64; $I^2 = 0.0\%$; $n = 3$).

Also, light drinking was marginally associated with a decreased incidence of both female and male thyroid cancer (RR, 0.89; 95% CI, 0.79-1.00; $I^2 = 0.0\%$; $n = 6$). There was no significant association between light drinking and the incidence of oropharyngeal cancer, head and neck cancer, oesophageal cancer, stomach cancer, liver cancer, pancreatic cancer, endometrial cancer, ovary cancer, prostate cancer, kidney cancer, bladder cancer, and hematologic malignancy.

Mortality

As shown in Table 3, light drinking reduced the mortality of female stomach cancer (RR, 0.65; 95% CI, 0.44-0.98; $n = 1$) and male lung cancer (RR, 0.79; 95% CI, 0.70-0.87; $I^2 = 0.0\%$; $n = 5$). There was no significant association between light drinking and the mortality of oropharyngeal cancer, oesophageal cancer, larynx cancer, colorectal cancer, liver cancer, female gall bladder cancer, pancreatic cancer, breast cancer, cervical cancer, prostate cancer, and hematologic malignancy.

Moderate alcohol drinking and the risk of cancer

Incidence

As shown in Table 2, moderate drinking (1-2 drinks/day) increased the incidence of both female and male oropharyngeal cancer (RR, 1.12; 95% CI, 1.01-1.24; $I^2 = 19.5\%$; $n = 3$), female oropharyngeal cancer (RR, 1.18; 95% CI, 1.05-1.33; $I^2 = 0.0\%$; $n = 3$), female larynx cancer (RR, 1.74; 95% CI, 1.25-2.41; $n = 1$), both female and male squamous cell oesophageal cancer (RR, 1.98; 95% CI, 1.25-3.14; $I^2 = 0.0\%$; $n = 2$), both female and male colorectal cancer (RR, 1.10; 95% CI, 1.03-1.19; $I^2 = 10.6\%$; $n = 6$), male colorectal cancer (RR, 1.19; 95% CI, 1.06-1.35; $I^2 = 10.6\%$; $n = 6$), female breast cancer (RR, 1.13; 95% CI,

1.11-1.15; $I^2 = 0\%$; $n = 15$), and both female and male malignant melanoma (RR, 1.77; 95% CI, 1.35-2.33; $I^2 = 0.0\%$; $n = 2$). Also, it was marginally significantly associated with an increased incidence of female and male liver cancer (RR, 1.26; 95% CI, 1.00-1.58; $I^2 = 0.0\%$; $n = 2$). On the contrary, moderate drinking reduced the incidence of both female and male kidney cancer (RR, 0.93; 95% CI, 0.86-1.00; $I^2 = 0.0\%$; $n = 3$), female kidney cancer (RR, 0.93; 95% CI, 0.80-0.94; $n = 1$), both female and male thyroid cancer (RR, 0.68; 95% CI, 0.56-0.84; $I^2 = 0.0\%$; $n = 3$), female thyroid cancer (RR, 0.67; 95% CI, 0.53-0.85; $I^2 = 0.0\%$; $n = 2$), and both female and male hematologic malignancy (RR, 0.89; 95% CI, 0.81-0.99; $I^2 = 52.3\%$; $n = 6$). There was no significant association between moderate drinking and the incidence of head and neck cancer, adenomatous oesophageal cancer and cardia, stomach cancer, pancreatic cancer, lung cancer, endometrial cancer, ovary cancer, prostate cancer, and bladder cancer.

Mortality

As shown in Table 3, overall moderate drinking was not associated with the mortality of most cancers. However, it increased the mortality of female colorectal cancer (RR, 2.51; 95% CI, 1.31- 4.82; $n = 1$) and female breast cancer (RR, 1.04; 95% CI, 1.01- 1.07; $I^2 = 0.0\%$; $n = 2$), while it reduced the mortality of male kidney cancer (RR, 0.46; 95% CI, 0.23- 0.93; $n = 1$).

Discussion

Principal findings

In the current large scale meta-analysis of cohort studies, we found that compared with non

or occasional alcohol drinking, very light (≤ 0.5 drink/day) or light (≤ 1 drink/day) did not increase the incidence of most cancers except for female breast cancer and male colorectal cancer by up to 9% and 6%, respectively. Conversely, light drinking was associated with a decreased incidence of both female and male lung cancer significantly and both female and male thyroid cancer marginally significantly. In the meantime, moderate drinking, i.e., 1 to 2 drink/day significantly increased the incidence of two types of cancer, male colorectal cancer and female breast cancer, whereas it decreased the incidence of both female and male hematologic malignancy. Also, there is a limitation to draw definite conclusions on the associations between very light or light drinking and the risk of several types of cancer such as lung cancer, malignant melanoma, and rectal cancer in incidence along with those associations in mortality and the associations between moderate drinking and the risk of most cancers except for male colorectal cancer, female breast cancer, and hematologic malignancy in both incidence and mortality because of a paucity of the included studies.

Comparison with previous findings

Our conclusion on the association between light drinking and the risk of cancer are inconsistent with those from a previous large scale meta-analysis of observational epidemiological studies. Bagnardi *et al*'s meta-analysis of 222 articles which included case-control studies and cohort studies published before December 2010 concluded that light drinking (1 drink/day) increased the risk of cancer of oral cavity, pharynx, oesophagus, and female breast [6]. As mentioned before in the introduction section, however, they did not consider the difference in findings between case-control studies and cohort studies and drew a wrong conclusion based on the findings from combining the results of both case-control studies and cohort studies. As Prof. Myung pointed out in his letter, except for breast cancer,

the subgroup meta-analysis of cohort studies which generally provide a higher level of evidence than case-control studies did not show any significant association between light alcohol drinking and the risk of cancers of oral cavity, pharynx, and oesophagus although light drinking was significantly associated with the increased risk of these cancers in the subgroup meta-analysis of case-control studies. Therefore, Bagnardi *et al*'s meta-analysis should have concluded that overall light drinking was not associated with the risk of cancer, although it increased the risk of female breast cancer slightly.

After the publication of Bagnardi *et al*'s meta-analysis, the 2015 newly revised ECAC 4th edition changed its recommendation on drinking from 'Moderate your consumption to two drinks per day if you are a man or one drink per day if you are a woman' to 'Not drinking is better for cancer prevention' based on the similar conclusions to those from Bagnardi *et al*. The ECAC 4th edition also did not consider the difference in findings between case-control studies and cohort studies and moreover wrongly used data for moderate drinking or just drinking instead of light drinking for the meta-analysis.

Meaning and implications of the current findings for policy makers and clinicians

In our study, except for only two types of cancer, female breast cancer and male colorectal cancer, very light or light drinking was not associated with the risk of most cancers. Although the incidence of malignant melanoma was increased with light drinking, it remains inconclusive due to a small number of included studies. As for female breast cancer, its incidence was increased at even the level of very light drinking (≤ 0.5 drink/day), which can be interpreted that there is no safe level for alcohol drinking regarding female breast cancer. Also, light drinking (≤ 1 drink/day) was associated with the increased incidence of male colorectal cancer. However, except for these two types of cancer, there was no sufficient

evidence to support that very light or light drinking up to 1 drink /day increases the risk of most of cancers. On the contrary, light drinking significantly decreased the incidence of both female and male lung cancer significantly and thyroid cancer marginally significantly. Thus, our findings imply that very light or light drinking has both benefits and harms in cancer prevention according to type of cancer.

Possible mechanisms for the main findings

The possible mechanisms on the association between alcohol consumption and the risk of breast cancer include the effect of alcohol on estrogen levels and estrogen receptor (ER) in mammary epithelial cells, the carcinogenic effect of ethanol metabolites, the effect of ethanol on epigenetic regulation of gene expression in the breast [12]. As for colon cancer, potential mechanisms to be examined in human-based studies are acetaldehyde production in the colon, cell proliferation due to ethanol or acetaldehyde exposure, and alterations in DNA repair mechanisms[13]. However, it still remains unclear why even very light or light drinking levels increase the incidence of female breast cancer and male colorectal cancer unlike the remaining common cancers.

In the meantime, very light or light drinking was associated with the decreased incidence of lung cancer significantly and thyroid cancer marginally significantly. It has been suggested that the protective effect of low or moderate alcohol consumption on lung cancer is attributable to its anti-inflammatory effects through lower plasma concentration of several systemic biomarkers of inflammation compared with no consumption [14], antioxidant effects in tumor promotion and progression [15], and anti-carcinogenic effects through induction of protective enzymes such as carcinogen detoxification enzymes [16,17]. However, it remains unclear why these effects would be specific for lung cancer. Also, the possible biological

mechanisms on the inverse association between alcohol consumption and the risk of thyroid cancer are the protective effect on developing thyroid cancer by decreased levels of thyroid-stimulating hormone and the direct toxic effect on thyroid cells and consequently reduction of thyroid volume [18].

Strengths of the current meta-analysis

This is the first meta-analysis of cohort studies that comprehensively investigated the association between very light and light alcohol drinking and the risk of a variety of cancers. Our study has its originality in that for the first time, we claim that overall light alcohol drinking is not associated with the risk of most of the common cancers except for female breast cancer and male colorectal cancer. Our findings refute the newly revised ECAC 4th edition on alcohol drinking and cancer and those from Bagnardi *et al*'s meta-analysis.

Limitations

There are several limitations in our study. First, except for breast cancer, colorectal cancer, and lung cancer, due to a paucity of data on very light or light drinking for most cancers, we were unable to clearly evaluate the associations between very light or light drinking and most cancers. Thus, further studies are necessary to confirm these associations. Second, there might be possible interactions between drinking and other factors such as smoking on the development of breast cancer and colorectal cancer. Although all the included cohort studies adjusted various factors in each multivariable analysis, those factors varied across studies. For example, however, because most studies included the important factors affecting the development of breast cancer such as age, smoking, age at menopause, age at first birth, family history of breast cancer, hormone replacement therapy, and oral contraceptives, the

effect of other unknown confounding factors would be minimal. Last, the generalization of our findings is limited because a small number of cohort studies among Asian populations were included in our analysis. More cohort studies are required to investigate that our findings can be applied to Asian populations.

Our meta-analysis of cohort studies found that compared with non or occasional alcohol drinking, very light or light drinking was not associated with the risk of most cancers except for female breast cancer and male colorectal cancer with a small increase in incidence. Although the IARC re-published ‘the ECAC 4th edition: Alcohol drinking and cancer’ in December 2016 [19] with a few corrections of data cited on the association between light alcohol drinking and cancer risk, they still did not consider the difference in findings between case-control studies and cohort studies and stick to the previously revised recommendation. Therefore, we suggest that the revision of the current ECAC 4th edition on alcohol drinking and cancer should be seriously considered from “If you drink alcohol of any type, limit your drinking. Not drinking is better for cancer prevention” to “If you drink alcohol of any type, limit your drinking. Not drinking is better in order to prevent breast cancer in women and colorectal cancer in men.”

Conflicts of Interest

Conflict of interest relevant to this article was not reported.

References

1. Humans IWGotEoCRt. Personal habits and indoor combustions. Volume 100 E. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum 2012;100(Pt E):1-538.
2. Boyle P, Autier P, Bartelink H, Baselga J, Boffetta P, Burn J, et al. European Code Against Cancer and scientific justification: third version (2003). *Ann Oncol.* 2003;14:973-1005.
3. Schuz J, Espina C, Villain P, Herrero R, Leon ME, Minozzi S, et al. European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk. *Cancer Epidemiol.* 2015;39 Suppl 1:S1-10.
4. Scoccianti C, Cecchini M, Anderson AS, Berrino F, Boutron-Ruault MC, Espina C, et al. European Code against Cancer 4th Edition: Alcohol drinking and cancer. *Cancer Epidemiol.* 2015;39 Suppl 1:S67-74.
5. Myung SK. Insufficient evidence on the association between light alcohol drinking and the risk of cancer: On the need for correction of the newly revised European Code against Cancer 4th edition. *Cancer Epidemiol.* 2016;44:174-5.
6. Myung SK. Erroneous conclusions about the association between light alcohol drinking and the risk of cancer: comments on Bagnardi et al.'s meta-analysis. *Ann Oncol.* 2016;27:2138.
7. Bagnardi V, Rota M, Botteri E, Tramacere I, Islami F, Fedirko V, et al. Light alcohol drinking and cancer: a meta-analysis. *Ann Oncol.* 2013;24:301-8.
8. Wells GA, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
9. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med.* 2002;21:1539-58.

10. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7:177-88.
11. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. *Res Synth Methods*. 2010;1:97-111.
12. Liu Y, Nguyen N, Colditz GA. Links between alcohol consumption and breast cancer: a look at the evidence. *Womens Health (Lond)*. 2015;11:65-77.
13. Oyesanmi O, Snyder D, Sullivan N, Reston J, Treadwell J, Schoelles KM. Alcohol consumption and cancer risk: understanding possible causal mechanisms for breast and colorectal cancers. *Evid Technol Assess (Full Rep)*. 2010;197:1-151.
14. Imhof A, Woodward M, Doering A, Helbecque N, Loewel H, Amouyel P, et al. Overall alcohol intake, beer, wine, and systemic markers of inflammation in western Europe: results from three MONICA samples (Augsburg, Glasgow, Lille). *Eur Heart J*. 2004;25:2092-100.
15. Bianchini F, Vainio H. Wine and resveratrol: mechanisms of cancer prevention? *Eur J Cancer Prev*. 2003;12:417-25.
16. Rohrmann S, Linseisen J, Boshuizen HC, Whittaker J, Agudo A, Vineis P, et al. Ethanol intake and risk of lung cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Am J Epidemiol*. 2006;164:1103-14.
17. Woodson K, Tangrea JA, Barrett MJ, Virtamo J, Taylor PR, Albanes D. Serum alpha-tocopherol and subsequent risk of lung cancer among male smokers. *J Natl Cancer Inst*. 1999;91:1738-43.
18. Hong SH, Myung SK, Kim H. Alcohol Intake and Risk of Thyroid Cancer: A Meta-analysis of Observational Studies. *Cancer Res Treat*. 2016. doi: 10.4143/crt.2016.161.

Fig. 1. Flow diagram of identification of relevant studies




Fig. 2. Association between light alcohol drinking (≤ 1 drink/day) and the risk of female breast cancer in a random-effects meta-analysis




Fig. 3. Association between light alcohol drinking (≤ 1 drink/day) and the risk of male colorectal cancer in a random-effects meta-analysis




Table 1. Number of articles and studies by organ site and country among 135 articles and 60 cohort studies

Category	Site of cancer	Incidence		Mortality	
		Number of articles	Number of studies	Number of articles	Number of studies
Upper digestive tract	Oral & Pharynx	5	5	2	2
	Oesophagus (SCC)	2	2		
	Oesophagus (ADC) & Cardia	3	3	5	4
	Head and Neck	2	2	NA	NA
Gastrointestinal tract	Stomach (Non-cardia)	11	9	2	2
	Colorectum	16	16		
	Colon	10	10	6	5
	Rectum	9	9		
Hepatobiliary system	Liver	2	2	2	2
	Pancreas	5	5	4	4
	Gall Bladder	NA	NA	1	1
Respiratory tract	Lung	10	10	6	5
	Larynx	1	1	1	1
Women's cancer	Breast (Female)	34	27	7	7
	Endometrium	9	9	NA	NA
	Ovary	5	5	NA	NA
	Cervix/Uterus	2	2	1	1
Men's cancer	Prostate	15	14	4	4
Urological system	Kidney	7	7	1	1

CANCER RESEARCH AND TREATMENT (CRT)

Others	Bladder	4	4	NA	NA
	Thyroid	6	6	NA	NA
	Hematologic Malignancy	8	8	2	2
	Malignant Melanoma	3	3	NA	NA
Category	Country	Incidence		Mortality	
		Number of articles	Number of studies	Number of articles	Number of studies
Asia	China	3	2	NA	NA
	Japan	5	4	2	2
	Korea	3	2	1	1
	Singapore	3	1	NA	NA
	Honk Kong	NA	NA	1	1
North America	US	70	28	9	9
	Canada	4	2	1	1
Europe	UK	5	5	NA	NA
	Sweden	6	3	NA	NA
	Norway	1	1	NA	NA
	Netherland	10	3	NA	NA
	Lithuania	2	2	NA	NA
	France	2	2	NA	NA
	Finland	1	1	NA	NA
	European countries	1	1	NA	NA
	Denmark	5	3	NA	NA

Table 2. Association between very light, light, and moderate alcohol drinking and cancer incidence

Site Of Cancer	Total No. of Study	Population	Very light drinking (≤ 0.5 drink/day)			Light drinking (≤ 1 drink/day)			Moderate drinking (1-2 drink/day)		
			No. of Study	RR (95% CI)	I ² (%)	No. of Study	RR (95% CI)	I ² (%)	No. of Study	RR (95% CI)	I ² (%)
Head & Neck	2	Women/Men	1	1.11 (0.75–1.65)	NA	2	1.00 (0.75–1.33)	0.0	2	1.18 (0.67–2.07)	63.8
Oral & Pharynx	5	Women/Men	0	NA	NA	4	0.96 (0.84–1.11)	68.9	3	1.12 (1.01–1.24)	19.5
		Women	0	NA	NA	3	0.95 (0.75–1.19)	77.6	3	1.18 (1.05–1.33)	0.0
		Men	0	NA	NA	1	0.89 (0.79–1.00)	NA	2	1.04 (0.93–1.17)	0.0
Larynx	1	Women/Men	0	NA	NA	0	NA	NA	0	NA	NA
		Women	0	NA	NA	1	1.13 (0.75–1.70)	NA	1	1.74 (1.25–2.41)	NA
		Men	0	NA	NA	0	NA	NA	0	NA	NA
Oesophagus (Squamous cell carcinoma)	2	Women/Men	1	0.85 (0.42–1.73)	NA	2	1.45 (0.90–2.33)	0.0	2	1.98 (1.25–3.14)	0.0
		Women	0	NA	NA	0	NA	NA	0	NA	NA
		Men	0	NA	NA	1	1.22 (0.62–2.44)	NA	1	1.87 (0.99–3.53)	NA
Oesophagus (adenocarcinoma)&Cardia	3	Women/Men	1	1.17 (0.69–1.98)	NA	3	0.83 (0.52–1.33)	44.5	3	0.81 (0.56–1.17)	0.0
		Women	0	NA	NA	0	NA	NA	0	NA	NA

CANCER RESEARCH AND TREATMENT (CRT)

		Men	0	NA	NA	0	NA	NA	0	NA	NA
Stomach, Non-Cardia	11	Women/Me n	3	1.00 (0.78–1.30)	0.0	7	1.00 (0.95–1.07)	0.0	6	0.91 (0.78–1.06)	0.0
		Women	1	1.11 (0.71–1.73)	NA	0	NA	NA	0	NA	NA
		Men	2	1.04 (0.66–1.64)	0.0	2	1.01 (0.92–1.11)	0.0	2	0.91 (0.68–1.20)	0.0
Colorectum	16	Women/Me n	6	1.10 (0.94–1.28)	39.7	14	1.04 (1.01–1.06)	0.0	10	1.10 (1.03–1.19)	41.0
		Women	2	0.92 (0.78–1.08)	0.0	7	1.02 (0.98–1.06)	0.0	5	1.04 (0.95–1.13)	4.4
		Men	3	1.31 (0.92–1.86)	47.3	6	1.06 (1.01–1.11)	0.0	6	1.19 (1.06–1.35)	10.6
Colon	10	Women/Me n	2	0.91 (0.55–1.49)	79.4	11	0.99 (0.93–1.05)	1.4	6	1.01 (0.88–1.15)	43.3
		Women	0	NA	NA	5	1.12 (0.90–1.40)	60.4	5	1.03 (0.91–1.17)	28.4
		Men	1	1.42 (0.83–2.45)	NA	5	1.02 (0.87–1.21)	0.0	5	1.08 (0.89–1.31)	0.0
Rectum	9	Women/Me n	2	1.47 (0.95–2.29)	0.0	10	1.04 (0.96–1.12)	0.5	7	1.03 (0.94–1.12)	0.0
		Women	0	NA	NA	4	1.02 (0.93–1.11)	0.0	3	0.99 (0.90–1.09)	0.0
		Men	0	NA	NA	3	1.07 (0.69–1.64)	0.0	2	1.35 (0.77–2.35)	0.0
Liver	2	Women/Me n	0	NA	NA	2	0.95 (0.76–1.20)	0.0	2	1.26 (1.00–1.58)	0.0
		Women	0	NA	NA	1	0.94 (0.72–1.21)	NA	1	1.20 (0.93–1.55)	NA
		Men	0	NA	NA	0	NA	NA	0	NA	NA
Pancreas	5	Women/Me n	4	1.06 (0.87–1.30)	0.0	3	1.02 (0.83–1.26)	6.3	3	1.03 (0.86–1.23)	0.0
		Women	0	NA	NA	0	NA	NA	1	1.01 (0.53–1.91)	NA
		Men	2	1.25 (0.90–1.74)	0.0	1	1.39 (0.75–2.56)	NA	1	1.24 (0.66–2.32)	NA

CANCER RESEARCH AND TREATMENT (CRT)

Lung	10	Women/Me n	3	0.89 (0.84–0.93)	6.9	10	0.91 (0.90–0.94)	0.0	8	0.98 (0.91–1.07)	50.0
		Women	2	0.82 (0.70–0.95)	12.9	4	0.90 (0.87–0.94)	0.0	4	1.05 (0.99–1.11)	0.0
		Men	1	0.86 (0.71–1.03)	NA	3	0.91 (0.90–0.95)	0.0	4	0.98 (0.82–1.16)	52.1
Breast (Female)	34	Women	20	1.04 (1.01–1.07)	3.7	25	1.09 (1.06–1.12)	32.8	15	1.13 (1.11–1.15)	0.0
Endometrium	9	Women	6	0.95 (0.80–1.12)	52.1	7	0.98 (0.93–1.03)	0.0	4	0.93 (0.84–1.04)	6.8
Ovary	5	Women	2	1.00 (0.82–1.22)	0.0	5	1.02 (0.88–1.20)	52.4	4	1.20 (0.92–1.56)	66.6
Cervix & Uterus	2	Women	NA	NA	NA	2	1.02 (0.88–1.19)	0.0	2	0.99 (0.83–1.17)	0.0
Prostate	15	Men	3	1.16 (0.94–1.44)	0.0	13	1.04 (0.97–1.11)	50.0	3	1.04 (0.96–1.11)	0.0
Kidney	7	Women/Me n	2	0.73 (0.50–1.08)	0.0	7	0.90 (0.81–1.00)	0.0	3	0.93 (0.86–1.00)	0.0
		Women	1	0.75 (0.45–1.29)	NA	2	0.79 (0.41–1.50)	66.9	1	0.93 (0.80–0.94)	NA
		Men	NA	NA	NA	3	0.90 (0.78–1.03)	0.0	1	0.94 (0.64–1.03)	NA
Bladder	4	Women/Me n	2	1.22 (0.82–1.82)	27.5	5	1.09 (0.97–1.23)	0.0	4	1.06 (0.77–1.47)	64.2
		Women	0	NA	NA	1	1.05 (0.92–1.21)	NA	1	0.91 (0.77–1.07)	NA
		Men	0	NA	NA	1	1.31 (0.80–2.13)	NA	0	NA	NA
Thyroid	6	Women/Me n	1	1.01 (0.76–1.36)	NA	6	0.89 (0.79–1.00)	0.0	3	0.68 (0.56–0.84)	0.0
		Women	0	NA	NA	5	0.89 (0.78–1.01)	0.0	2	0.67 (0.53–0.85)	0.0
		Men	0	NA	NA	1	0.62 (0.25–1.54)	NA	1	0.69 (0.40–1.20)	NA
Hematologic Malignancy	8	Women/Me n	3	1.05 (0.87–1.26)	15.1	6	0.98 (0.91–1.05)	41.4	6	0.89 (0.81–0.99)	52.3

Malignant Melanoma	3	Women	1	1.16 (0.88–1.54)	NA	4	0.99 (0.93–1.06)	0.0	3	0.91 (0.81–1.02)	0.0
		Men	0	NA	NA	2	0.98 (0.81–1.19)	54.2	2	0.90 (0.78–1.04)	0.0
		Women/Me n	0	NA	NA	3	1.44 (1.18–1.76)	0.0	2	1.77 (1.35–2.33)	0.0
		Women	0	NA	NA	2	1.32 (0.97–1.79)	0.0	1	1.70 (0.90–3.10)	NA
		Men	0	NA	NA	0	NA	NA	1	0.90 (0.20–3.00)	NA

RR, relative risk; CI, confidence interval; NA, not applicable.

Table 3. Association between very light, light, and moderate alcohol drinking and cancer mortality

Site of cancer	Total no. of Study	population	Very light drinking (≤0.5 drink/day)			Light drinking (≤1 drink/day)			Moderate drinking (1-2 drink/day)		
			No. of Study	RR (95% CI)	I ² (%)	No. of Study	RR(95% CI)	I ² (%)	No. of Study	RR(95% CI)	I ² (%)
Oral & Pharynx	2	women/men	0	NA	NA	0	NA	NA	0	NA	NA
		women	0	NA	NA	0	NA	NA	0	NA	NA
		men	0	NA	NA	2	0.71 (0.24–2.16)	72.0	1	0.75 (0.27–2.06)	NA
Oesophagus	4	women/men	0	NA	NA	0	NA	NA	0	NA	NA
		women	0	NA	NA	0	NA	NA	0	NA	NA
		men	0	NA	NA	4	1.17 (0.98–1.39)	0.0	2	1.46 (0.93–2.16)	0.0
Larynx	1	women/men	0	NA	NA	0	NA	NA	0	NA	NA
		women	0	NA	NA	0	NA	NA	0	NA	NA
		men	0	NA	NA	1	1.31 (0.60–2.85)	NA	1	0.87 (0.32–2.35)	NA
Stomach	2	women/men	0	NA	NA	3	0.81 (0.58–1.12)	49.5	2	1.11 (0.79–1.56)	43.6
		women	0	NA	NA	1	0.65 (0.44–0.98)	NA	1	1.48 (0.85–2.57)	NA
		men	0	NA	NA	2	0.95 (0.83–1.10)	0.0	1	1.00 (0.85–1.18)	NA
Colorectum	6	women/men	2	0.88 (0.70–1.12)	0.0	6	0.97 (0.83–1.14)	32.6	2	1.55 (0.67–3.58)	82.4
		women	1	0.74 (0.53–1.03)	NA	4	0.79 (0.58–1.06)	26.3	1	2.51 (1.31–4.82)	NA
		men	2	1.06 (0.72–1.55)	0.0	5	1.11 (0.95–1.28)	0.0	1	1.06 (0.80–1.40)	NA
Liver	2	women/men	0	NA	NA	2	0.92 (0.81–1.04)	0.0	2	1.00 (0.88–1.14)	37.7
		women	0	NA	NA	2	0.78 (0.48–1.25)	0.0	1	1.80 (0.90–1.10)	NA
		men	0	NA	NA	2	0.93 (0.81–1.06)	0.0	2	0.98 (0.91–1.07)	0.0
Gall Bladder	1	women/men	0	NA	NA	0	NA	NA	0	NA	NA
		women	1	1.49 (0.59–3.74)	NA	1	1.14 (0.28–4.70)	NA	0	NA	NA

CANCER RESEARCH AND TREATMENT (CRT)

		men	0	NA	NA	0	NA	NA	0	NA	NA
Pancreas	4	women/men	0	NA	NA	4	0.93 (0.78–1.11)	22.0	1	0.95 (0.72–1.27)	0.0
		women	0	NA	NA	1	0.66 (0.35–1.23)	NA	1	0.50 (0.12–2.05)	NA
		men	1	0.52 (0.23–1.15)	NA	3	1.01 (0.55–1.85)	55.8	1	0.98 (0.73–1.31)	NA
Lung	5	women/men	2	0.81 (0.69–0.94)	0.0	6	0.90 (0.79–1.04)	49.3	0	NA	NA
		women	1	0.70 (0.56–0.89)	NA	3	1.03 (0.80–1.31)	43.1	1	0.94 (0.45–1.94)	NA
		men	2	0.84 (0.68–1.03)	0.0	5	0.79 (0.70–0.87)	0.0	1	0.78 (0.68–0.90)	NA
Breast	7	women	2	0.79 (0.64–0.97)	0.0	6	1.06 (0.97–1.16)	31.5	2	1.04 (1.01–1.07)	0.0
Cervix/Uterus	1	women	0	NA	NA	1	1.09 (0.50–2.35)	NA	1	1.10 (0.25–4.79)	NA
Prostate	4	men	2	0.92 (0.68–1.25)	0.0	1	1.14 (0.85–1.52)	0.0	1	1.75 (0.72–4.22)	NA
Kidney	1	women/men	0	NA	NA	0	NA	NA	0	NA	NA
		women	0	NA	NA	0	NA	NA	0	NA	NA
		men	0	NA	NA	1	0.63 (0.35–1.12)	NA	1	0.46 (0.23–0.93)	NA
Hematologic Malignancy	2	women/men	0	NA	NA	2	1.24 (0.40–3.86)	55.6	1	1.00 (0.63–1.60)	NA
		women	0	NA	NA	1	3.26 (0.79–13.48)	NA	0	NA	NA
		men	1	0.87 (0.49–1.53)	NA	3	0.80 (0.54–1.18)	1.9	1	1.00 (0.63–1.60)	NA

RR, relative risk; CI, confidence interval; NA, not applicable.

Supplementary Material

S1Table. General characteristics of the studies included in the final analysis - cancer incidence

Study	Country	Cohort	Enroll year	Population	Cancer type	Alcohol consumption amount (baseline)	RR (95% CI)
Oral cavity and pharyngeal cancer							
2007 Freedman ¹	US	NIH-AARP Diet and Health Study	1995-2000	men (492960 men/women) women	oral cavity	0 drinks/day <1 drink/day 1-3 drinks/day 0 drinks/day <1 drink/day 1-3 drinks/day	1.43 (1.03 - 2.00) 1.0 1.22 (0.85 - 1.76) 1.24 (0.74 - 2.10) 1.0 1.74 (0.95 - 3.20)
2009 Allen ²	UK	Million Women Study	1996–2001	1280296 Women	Oral cavity & pharyngeal cancer	Nondrinkers 3 to 6 drinks/wk 7 to 14 drinks/wk	1.18 (1.02 to 1.36) 1.13 (0.97 to 1.32) 1.13 (0.96 to 1.34)
2010 Shanmugham ³	US	Nurses' Health Study	1980–2006	87621 Women (30–55yrs)	Oral cancer	0 0.1 to 14.9 g/day	1.00 0.59 (0.39 to 0.87)
2015 Hippisley–Cox ⁴	UK	Primary care patients from open cohort study using Qresearch database (EMIS computer system)	1998–2013	Women Men	Oral cancer Oral cancer	Nondrinkers <1 unit/day 1–2 units/day Nondrinkers <1 unit/day 1–2 units/day	1.0 1.03 (0.91 to 1.16) 1.18 (0.99 to 1.40) 1.0 0.89 (0.79 to 1.00) 1.02 (0.90 to 1.15)
2007 Friborg ⁵	Singapore	Singapore Chinese Health Study	1993–2005	61320 Women/Men(4 5–74yrs) (34028 Women, 27292 Men)	Nasopharyngeal carcinoma Oropharyngeal carcinoma	Nondrinkers 1 to 7 drinks/wk Nondrinkers 1 to 7 drinks/wk	1.00 0.9 (0.6 to 1.4) 1.00 1.4 (0.8 to 2.7)

Laryngeal cancer							
2009 Allen ²	UK	Million Women Study	1996–2001	1280296 Women	Laryngeal cancer	Nondrinkers	1.09 (0.79 to 1.52)
						1 to 2 drinks/wk	1.00
						3 to 6 drinks/wk	1.13 (0.75 to 1.70)
						7 to 14 drinks/wk	1.74 (1.25 to 2.41)
Head and neck cancer							
2013 Hashibe ⁶	US	Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Cohort(PLCO)	1992–2001	101182 Women/Men(5 5–74yrs)	Head and neck cancer	Nondrinkers	1.00
						>0 to <1 drink/day	0.87 (0.58 to 1.29)
						1 to 1.9 drink/day	0.85 (0.49 to 1.49)
2014 Maasland ⁷	Netherlands	Netherlands Cohort Study	1986–2003	120852 Women/Men	Head and neck cancer	Abstainers	1.00
						>0 to <5 g/day	1.11 (0.75 to 1.65)
						5 to <15 g/day	1.15 (0.77 to 1.71)
						15 to <30 g/day	1.52 (1.02 to 2.27)
Esophageal cancer (squamous cell carcinoma)							
2008 Fan ⁸	China	Shanghai Cohort Study	1986–2006	18244 Men	Esophageal cancer	Nondrinkers	1.00
						>0 to <1 drink/day	1.22 (0.62 to 2.44)
						1 to <2 drinks/day	1.87 (0.99 to 3.53)
2010 Steevens ⁹	Netherlands	Netherlands Cohort Study	1986–2002	120852 Women/Men	Esophageal cancer	Abstainers	1
						>0 to <5 g/day	1.85 (0.42 to 1.73)
						5 to <15 g/day	1.65 (0.85 to 3.17)
						15 to <30 g/day	2.11 (1.08 to 4.14)
Esophageal and gastric cardia adenocarcinoma							
2009 Allen ²	UK	Million Women Study	1996–2001	1280296 Women	Esophageal ADC	Nondrinkers	1.28 (1.01 to 1.63)
						1 to 2 drinks/wk	1.00
						3 to 6 drinks/wk	1.25 (0.96 to 1.62)

						7 to 14 drinks/wk	0.77 (0.53 to 1.13)
2010 Steevens ⁹	Netherland	Netherlands Cohort Study	1986–2002	120852 Women/Men	Esophageal ADC	Abstainers	1.00
						>0 to <5 g/day	1.17 (0.69 to 1.98)
						5 to <15 g/day	0.91 (0.51 to 1.60)
						15 to <30 g/day	1.01 (0.56 to 1.82)
					Gastric cardia ADC	Abstainers	1.00
						>0 to <5 g/day	0.75 (0.44 to 1.30)
						5 to <15 g/day	1.11 (0.68 to 1.82)
						15 to <30 g/day	0.92 (0.54 to 1.57)
2014 Yates ¹⁰	UK	EPIC–Norfolk Study	1993–2008	24068 Women/Men	Esophageal ADC	No alcohol	1.00
						>0 to <7 units/wk	1.34 (0.63 to 2.88)
						7 to <14 units/wk	0.73 (0.28 to 1.86)
						14 to <21 units/wk	0.47 (0.12 to 1.79)
Gastric cancer							
1995 Nomura ¹¹	Japan	American Men of Japanese ancestry residing in Hawaiian island	1965–1990	7972 Men	Gastric cancer	Nondrinkers	1.0
						<5 oz/month	0.9 (0.6 to 1.3)
						5–14 oz/month	1.1 (0.8 to 1.6)
1998 Galanis ¹²	US	Japanese residents of Hawaii	1975–1994	11907 Women/Men (6297 Women, 5610 Men)	Gastric cancer	Nondrinkers	1.00
						1–2 drinks/day	0.50 (0.2 to 1.1)
2005 Barstad ¹³	Denmark	Copenhagen Center for Prospective Population Studies (Copenhagen City Heart Study, Copenhagen Male Study, Copenhagen County Center for Preventive Medicine)	1964–1997	28463 Women/Men 13227 Women 15236 Men	Gastric cancer	<1 drink/wk	1.00
						1–6 drinks/wk	1.47 (0.93 to 2.02)
						7–13 drinks/wk	0.95 (0.32 to 1.58)

2007 Larsson ¹⁴	Sweden	Swedish Mammography Cohort	1987–2005	61433 Women	Gastric cancer	Nondrinkers	1.00
						0.1 to 19.9 g/wk	0.85 (0.58 to 1.25)
						20.0 to 39.9 g/wk	1.18 (0.73 to 1.91)
2007 Sung ¹⁵	Korea	National Health Insurance Corporation Study	1996–2002	669570 Men	Gastric cancer	0	1.0
						1 to 14.9 g/day	1.0 (0.9 to 1.1)
						15.0 to 24.9 g/day	1.1 (1.0 to 1.3)
2009 Allen ²	UK	Million Women Study	1996–2001	1280296 Women	Gastric cancer	Nondrinkers	1.27 (1.12 to 1.44)
						3 to 6 drinks/wk	1.06 (0.91 to 1.22)
						7 to 14 drinks/wk	0.79 (0.65 to 0.95)
2010 Moy ¹⁶	China	Shanghai Cohort Study	1986–2005	18244 Men	Gastric cancer	Nondrinkers	1.00
						>0 to <20 g/day	0.88 (0.67 to 1.16)
2010 Steevens ⁹	Netherlands	Netherlands Cohort Study	1986–2002	120852 Women/Men	Gastric non-cardia ADC	Abstainers	1.00
						>0 to <5 g/day	0.92 (0.69 to 1.23)
						5 to <15 g/day	1.07 (0.80 to 1.43)
						15 to <30 g/day	0.77 (0.55 to 1.08)
2012 Everatt ¹⁷	Lithuania	Kaunas Rotterdam Intervention Study (KRIS), Multifactorial Ischemic Heart Disease Prevention Study (MIHDPS)	1972–2008	7150 Men (40–59yrs)	Gastric cancer	0.1 to 9.9 g/wk	1.00
						10.0 to 24.9 g/wk	1.04 (0.66 to 1.64)
						25.0 to 99.9 g/wk	1.44 (0.91 to 2.29)
2015 Eom ¹⁸	Korea	Korean National Health Insurance Corporation data	1998–2007	2291132 Women/Men	Gastric cancer	0	1
						1–14.9 g/day	0.98 (0.89 to 1.06)
						>15 g/day	1.16 (0.99 to 1.36)
2015 Klatsky ¹⁹	US	Multiethnic Northern California population (Kaiser	1978–2012	124193 Women/Men	Gastric cancer	Never drinkers	1.0
						<1 drink/day	0.9 (0.7 to 1.2)

Permanente)						1 to 2 drinks/day	0.8 (0.6 to 1.4)
Colorectal cancer							
2002 Flood ²⁰	US	Breast Cancer Detection Demonstration Project (BCDDP)	1987–1995	45264 Women	Colorectal cancer	0 0.01 to 0.50 servings/day 0.51 to 1.00 servings/day 1.01 to 2.00 servings/day	1.00 0.92 (0.73 to 1.16) 1.00 (0.74 to 1.35) 0.94 (0.62 to 1.42)
2003 Otani ²¹	Japan	Japan Public Health Center–based prospective study (cohort I)	1990–1999	90004 Women/Men	Colorectal cancer	Never drinkers, ex–drinkers occasional drinkers regular drinkers (1–149 g/wk)	1.0 0.8 (0.4 to 1.4) 0.9 (0.6 to 1.4)
2004 Sanjoquin ²²	UK	Oxford Vegetarian Study	1980–1999	10998 Women/Men (6836 Women, 4162 Men)	Colorectal cancer	<1 drink/wk 1–7 drinks/wk	1.00 1.53 (0.94 to 2.49)
2005 Chen ²³	China	Population of Jiashan County	1989–2001	64100 Women/Men 33148 Women 30952 Men	Colorectal cancer	Nondrinkers occasional (<7drinks/wk) daily (≥7drinks/wk) Nondrinkers occasional (<7drinks/wk) daily (≥7drinks/wk) Nondrinkers occasional (<7drinks/wk) daily (≥7drinks/wk)	1 1.13 (0.79 to 1.64) 1.11 (0.74 to 1.67) 1 1.33 (0.78 to 2.26) 1.06 (0.33 to 3.48) 1 0.99 (0.61 to 1.63) 1.03 (0.65 to 1.64)
2007 Tsong ²⁴	Singapore	Singapore Chinese Health Study	1993–1998	63257 Women/Men	Colorectal cancer	Nondrinkers <7 drinks/wk	1.00 0.96 (0.72 to 1.25)
2008 Bongaerts ²⁵	Netherlands	Netherlands Cohort Study	1986–1999	120852 Women/Men	Colorectal cancer	Abstainers	1.00

				(62573 Women, 58279 Men, 55–69 yrs)		0 to <5.0 g/day 5.0 to 15.0 g/day 15.0 to <30.0 g/day	1.06 (0.91 to 1.23) 0.97 (0.82 to 1.14) 1.00 (0.83 to 1.20)
				62573 Women		Abstainers	1.00
						0 to <30.0 g/day	0.91 (0.74 to 1.12)
				58279 Men		Abstainers	1.00
						0 to <30.0 g/day	1.16 (0.91 to 1.48)
2008 Kabat ²⁶	Canada	Canadian National Breast Screening Study	1980–2000	49654 Women	Colorectal cancer	Never >0 to <5g/day 5 to <10 g/day 10 to <20 g/day 20 to <30 g/day	1.00 0.92 (0.73 to 1.14) 0.93 (0.71 to 1.22) 1.04 (0.79 to 1.36) 1.13 (0.77 to 1.64)
2008 Thygesen ²⁷	US	Health Professional Follow– up Study	1986–2002	47432 Men	Colorectal cancer	Nondrinkers 0.1 to 5 g/day 5.1 to 10 g/day 10.1 to 20 g/day 20.1 to 30 g/day	1 1.05 (0.79 to 1.40) 1.30 (0.96 to 1.76) 1.38 (1.04 to 1.83) 1.43 (0.99 to 2.07)
2008 Toriola ²⁸	Finland	Kuopio Ischemic Heart Study (KIHD)	1984–2005	2682 Men	Colorectal cancer	0 to 3.2 g/wk 3.3 to 17.2 g/wk 17.3 to 48.8 g/wk 48.9 to 115.2 g/wk	1 2.4 (0.9 to 6.8) 2.5 (0.9 to 7.2) 2.2 (0.8 to 6.4)
2009 Park ²⁹	UK	UK Norfolk arm of EPIC study	1995–2003	25639 Women/Men (40–79yrs)	Colorectal cancer	Nondrinkers >0–<7drinks/wk 7 to <14 drinks/wk	1.00 0.91 (0.69 to 1.21) 0.74 (0.52 to 1.07)
				14032 Women		>0–<7drinks/wk	0.79 (0.55 to 1.14)

				11607 Men		7 to <14 drinks/wk	0.60 (0.34 to 1.05)
						>0–<7drinks/wk	1.18 (0.74 to 1.87)
						7 to <14 drinks/wk	0.97 (0.57 to 1.64)
2011 Razzak ³⁰	US	Iowa Women's Health Study	1986–2004	38001 Women	Colorectal cancer	Nondrinkers	1.00
						>0 to ≤1.8 g/day	1.04 (0.88 to 1.24)
						1.80 to ≤3.4 g/day	0.92 (0.74 to 1.15)
						3.4 to ≤11 g/day	1.10 (0.91 to 1.33)
2013 Everatt ³¹	Lithuania	Kaunas Rotterdam Intervention Study (KRIS), Multifactorial Ischemic Heart Disease Prevention Study (MIHDPS)	1978–2008	7150 Men	Colorectal cancer	Nondrinker	1.24 (0.72 to 2.16)
						0.1 to 10 g/wk	1.00
						10.1 to 40.0 g/wk	1.46 (1.01 to 2.11)
						40.1 to 70.0 g/wk	0.81 (0.41 to 1.60)
						70.1 to 140.0 g/wk	1.32 (0.83 to 2.09)
2014 Nishihara ³²	US	Nurses' Health Study, Health Professionals Follow-up Study	1976–2008	173230 Women/Men (121701 Women, 51529 Men)	Colorectal cancer	0	1.00
						1 to 14 g/day	1.13 (0.97 to 1.32)
2015 Cho ³³	Korea	Korean Multi-center Cancer Cohort	1993–2005	18707 Women/Men	Colorectal cancer	Never drinkers	1.0
				Women		<10 g/day	0.82 (0.41 to 1.63)
						10–29 g/day	0.95 (0.23 to 3.87)
				Men		<10 g/day	1.28 (0.71 to 2.31)
						10–29 g/day	1.77 (0.96 to 3.26)
						Never drinkers	1.0
2015 Hippisley–Cox ⁴	UK	Primary care patients from open cohort study using Qresearch database (EMIS computer system)	1998–2013	4960000 Women/Men	Colorectal cancer	Nondrinkers	1.0
				Women		<1 unit/day	1.02 (0.98 to 1.06)
						1–2 units/day	1.05 (1.00 to 1.11)

				Men		<1 unit/day	1.05 (1.00 to 1.10)
						1–2 units/day	1.14 (1.08 to 1.20)
2015 Klatsky ¹⁹	US	Multiethnic Northern California population (Kaiser Permanente)	1978–2012	124193 Women/Men	Colorectal cancer	Never drinkers	1.00
						<1 drink/day	1.1 (1.0 to 1.3)
						1 to 2 drinks/day	1.2 (1.0 to 1.4)
Colon cancer							
1988 Klatsky ³⁴	US	Members of Kaiser Permanente Medical Care Program in Northern California	1978–1984	106203 Women/Men	Colon cancer	None	1.0
						>0 –<1 drinks/day	1.16 (0.75 to 1.79)
						1 to 2 drinks/day	1.59 (0.95 to 2.64)
				Women		>0 –<1 drinks/day	1.29 (0.77 to 2.17)
						1 to 2 drinks/day	1.80 (0.92 to 3.52)
				Men		>0 –<1 drinks/day	0.89 (0.41 to 1.98)
						1 to 2 drinks/day	1.15 (0.50 to 2.64)
1990 Stemmermann ³⁵	US	American Men of Japanese ancestry residing in Hawaiian island (Oahu)	1965–1989	8006 Men	Colon cancer	0	1.0
						>0 to <5 oz/month	0.68 (0.45 to 1.05)
						5 to 14 oz/month	0.96 (0.63 to 1.47)
						15 to 39 oz/month	1.16 (0.78 to 1.72)
1994 Goldbohm ³⁶	Netherlands	from 204 municipal population registries throughout the country	1986–1989	120852 Women/Men (62573 Women, 58279 Men, 55–69yrs)	Colon cancer	Abstainers	1.0
						0.1 to 4.9 g/day	0.7 (0.5 to 1.0)
						5.0 to 14.9 g/day	0.6 (0.4 to 0.9)
						15.0– 29.9 g/day	0.9 (0.5 to 1.6)
1995 Giovannucci ³⁷	US	Male health professionals	1986–1992	47931 Men (40–75yrs)	Colon cancer	0 to 0.25 drinks/day	1.0
						0.26 to 0.50 drinks/day	1.42 (0.83 to 2.45)

						0.51 to 1.0 drink/day	1.67 (1.03 to 2.69)
						1.1 to 2.0 drinks/day	1.68 (1.03 to 2.74)
2003 Pederson ³⁸	Denmark	Copenhagen Center for Prospective Population Studies (Copenhagen City Heart Study, Copenhagen Male Study, Copenhagen County Center for Preventive Medicine)	-1999, median 14.7yrs	29132 Women/Men (23–95yrs)	Colon cancer	<1 drink/wk 1 to 6 drinks/wk 7 to 13 drinks/wk	1.00 1.0 (0.8 to 1.3) 0.9 (0.7 to 1.2)
2004 Su ³⁹	US	National Health and Nutrition Examination Survey (NHANES I)	1982–1993	10220 Women/Men (55970 Women, 50040 Men)	Colon cancer	0 <1 drink/day	1.00 1.08 (0.65 to 1.79)
2004 Wei ⁴⁰	US	Nurses' Health Study, Health Professionals Follow-up Study	NHS 1980–2000, HPFS 1986–2000	134365 Women/Men 87733 Women 46632 Men		<10 g/day 10–19 g/day 0 <10 g/day 10–19 g/day 0 <10 g/day 10–19 g/day	0.97 (0.82 to 1.14) 1.04 (0.85 to 1.26) 1.00 0.97 (0.81 to 1.17) 0.99 (0.78 to 1.27) 1.00 1.08 (0.75 to 1.55) 1.27 (0.86 to 1.86)
2005 Chen ²³	China	Population of Jiashan County	1989–2001	64100 Women/Men 33148 Women 30952 Men	Colon cancer	Nondrinkers occasional (<7drinks/wk) Nondrinkers occasional (<7drinks/wk) Nondrinkers occasional (<7drinks/wk)	1.00 1.06 (0.61 to 1.83) 1.00 1.23 (0.52 to 2.91) 1.00 0.87 (0.44 to 1.74)

2007 Tsong ²⁴	Singapore	Singapore Chinese Health Study	1993–1998	63257 Women/Men	Colon cancer	Nondrinkers <7 drinks/wk	1.00 0.96 (0.72 to 1.25)
2008 Bongaerts ²⁵	Netherlands	Netherlands Cohort Study	1986–1999	120852 Women/Men (55–69yrs)	Colon cancer	Abstainers 0 to <5.0 g/day 5.0 to 15.0 g/day 15.0 to <30 g/day	1.00 1.03 (0.87 to 1.22) 0.93 (0.78 to 1.13) 0.93 (0.75 to 1.14)
				62573 Women 58279 Men		0 to <30.0 g/day 0 to <30.0 g/day	0.91 (0.72 to 1.15) 1.00 (0.75 to 1.34)
2009 Allen ²	UK	Million Women Study	1996–2001	1280296 Women	Colon cancer	Nondrinkers 1 to 2 drinks/wk 3 to 6 drinks/wk 7 to 14 drinks/wk	1.00 (0.94 to 1.07) 1.00 0.99 (0.93 to 1.06) 1.02 (0.95 to 1.09)
2009 Park ²⁹	UK	UK Norfolk arm of EPIC study	1995–2003	25639 Women/Men (40–79yrs)	Colon cancer	Nondrinkers >0–<7drinks/wk 7 to <14 drinks/wk	1.00 0.93 (0.66 to 1.31) 0.64 (0.41 to 1.01)
				Women		>0–<7drinks/wk 7 to <14 drinks/wk	0.85 (0.54 to 1.33) 0.59 (0.29 to 1.17)
				Men		>0–<7drinks/wk 7 to <14 drinks/wk	1.10 (0.63 to 1.90) 0.75 (0.39 to 1.43)
2012 Cho ⁴¹	US	Health Professional Follow-up Study, Nurses' Health Study	1980–2006	135151 Women/Men		None 0.1 to <5 g/day 5.0 to <10 g/day 10 to <15 g/day 15 to < 30 g/day	1.00 1.16 (0.87 to 1.54) 1.08 (0.91 to 1.28) 1.26 (0.96 to 1.66) 1.11 (0.92 to 1.33)

				87861 Women		None	1.00
						15 to < 30 g/day	1.11 (0.85 to 1.45)
						0.1 to <5 g/day	1.32 (1.12 to 1.56)
						5.0 to <10 g/day	1.09 (0.87 to 1.36)
						10 to <15 g/day	1.43 (1.13 to 1.82)
						15 to < 30 g/day	1.11 (0.86 to 1.43)
				47290 Men	Colon cancer	None	1.00
						0.1 to <5 g/day	0.99 (0.78. to 1.25)
						5.0 to <10 g/day	1.07 (0.82 to 1.39)
						10 to <15 g/day	1.08 (0.82 to 1.44)
Rectal cancer							
1988 Klatsky ³⁴	US	Members of Kaiser Permanente Medical Care Program in Northern California	1978–1984	106203 Women/Men	Rectal cancer	None	1.0
						>0 –<1 drinks/day	1.42 (0.57 to 3.55)
						1 to 2 drinks/day	2.28 (0.83 to 6.26)
1990 Stemmermann ³⁵	US	American Men of Japanese ancestry residing in Hawaiian island (Oahu)	1965–1989	8006 Men	Rectal cancer	0	1.0
						>0 to <5 oz/month	0.86 (0.45 to 1.62)
						5 to 14 oz/month	1.69 (0.96 to 2.99)
						15 to 39 oz/month	1.45 (0.80 to 2.61)
1994 Goldbohm ³⁶	Netherlands	204 municipal population registries throughout the country	1986–1989	120852 Women/Men (55–69yrs)	Rectal cancer	Abstainers	1.0
						0.1 to 4.9 g/day	1.2 (0.6 to 2.4)
						5.0 to 14.9 g/day	0.8 (0.4 to 1.6)
						15.0– 29.9 g/day	1.5 (0.7 to 3.2)
2003 Pederson ³⁸	Denmark	Copenhagen Center for Prospective Population	(~1999, median	29132 Women/Men(2	Rectal cancer	<1 drink/wk	1.00
						1 to 6 drinks/wk	1.5 (0.9 to 2.3)

		Studies (Copenhagen City Heart Study, Copenhagen Male Study, Copenhagen County Center for Preventive Medicine)	14.7yrs	3–95yrs)		7 to 13 drinks/wk	1.5 (0.9 to 2.5)
2004 Wei ⁴⁰	US	Nurses' Health Study (NHS), Health Professionals Follow-up Study (HPFS)	NHS 1980–2000, HPFS 1986–2000	134,365 Women/Men	Rectal cancer	0	1.00
						<10 g/day	1.04 (0.77 to 1.40)
						10–19 g/day	1.07 (0.75 to 1.55)
				87733 Women		0	1.00
						<10 g/day	1.12 (0.80 to 1.58)
						10–19 g/day	0.96 (0.60 to 1.54)
				46632 Men		0	1.00
						<10 g/day	0.93 (0.47 to 1.82)
						10–19 g/day	1.31 (0.66 to 2.62)
2005 Chen ²³	China	Population of Jiashan County	1989–2001	64100 Women/Men	Rectal cancer	Nondrinkers	1.00
						occasional (<7drinks/wk)	1.20 (0.73 to 1.98)
				33148 Women		Nondrinkers	1.00
						occasional (<7drinks/wk)	1.38 (0.70 to 2.71)
				30952 Men		Nondrinkers	1.00
						occasional (<7drinks/wk)	1.15 (0.56 to 2.35)
2007 Tsong ²⁴	Singapore	Singapore Chinese Health Study	1993–1998	63257 Women/Men	Rectal cancer	Nondrinkers	1.00
						<7 drinks/wk	1.22 (0.17 to 2.35)
2008 Bongaerts ²⁵	Netherlands	Netherlands Cohort Study	1986–1999	120852 Women/Men (55–69yrs)	Rectal cancer	Abstainers	1.00
						0 to <5.0 g/day	1.10 (0.83 to 1.45)
						5.0 to 15.0 g/day	1.00 (0.74 to 1.34)
						15.0 to <30 g/day	1.04 (0.75 to 1.44)

					58279 Men	Abstainers	1.00
						0 to <30.0 g/day	1.23 (0.80 to 1.89)
					62573 Women	Abstainers	1.00
						0 to <30.0 g/day	0.90 (0.58 to 1.40)
2009 Allen ²	UK	Million Women Study	1996–2001	1280296 Women	Rectal cancer	Nondrinkers	0.94 (0.86 to 1.03)
						1 to 2 drinks/wk	1.00
						3 to 6 drinks/wk	1.01 (0.92 to 1.11)
						7 to 14 drinks/wk	1.0 (0.97 to 1.18)
2009 Park ²⁹	UK	UK Norfolk arm of EPIC study	1995–2003	25639 Women/Men (40–79yrs)	Rectal cancer	Nondrinkers	1.00
						>0 to <7drinks/wk	0.87 (0.52 to 1.46)
						7 to <14 drinks/wk	0.96 (0.52 to 1.77)
					Men	Nondrinkers	1.00
						>0 to <7drinks/wk	1.2 (0.50 to 2.97)
						7 to <14 drinks/wk	1.42 (0.55 to 3.65)
					Women	Nondrinkers	1.00
						>0 to <7drinks/wk	0.73 (0.38 to 1.41)
						7 to <14 drinks/wk	0.68 (0.27 to 1.74)
Liver cancer							
2009 Allen ²	UK	Million Women Study	1996–2001	1280296 Women	Liver cancer	Nondrinkers	1.41 (1.16 to 1.72)
						1 to 2 drinks/wk	1.00
						3 to 6 drinks/wk	0.94 (0.72 to 1.21)
						7 to 14 drinks/wk	1.20 (0.93 to 1.55)
2015 Klatsky ¹⁹	US	Multiethnic Northern California population (Kaiser Permanente)	1978–2012	124193 Women/Men	Liver cancer	Never drinkers	1.00
						<1 drink/day	1.0 (0.6 to 1.5)
						1 to 2 drinks/day	1.5 (0.9 to 2.5)

Pancreatic cancer							
2001 Michaud ⁴²	US	Nurses' Health Study	1980–1996	88799 Women (30–55yrs)	Pancreatic cancer	0	1.0
						0.1 to 1.4 g/day	0.72 (0.41 to 1.30)
						1.5 to 4.9 g/day	1.07 (0.68 to 1.67)
						5.0 to 29.9 g/day	0.93 (0.61 to 1.42)
		Health Professionals Follow-up Study	1986–1994	47794 Men (40–75yrs)		0	1.0
						0.1 to 1.4 g/day	1.01 (0.36 to 2.83)
						1.5 to 4.9 g/day	1.44 (0.67 to 3.12)
						5.0 to 29.9 g/day	1.23 (0.59 to 2.53)
		Pooled		136593 Women/Men		0	1.0
						0.1 to 1.4 g/day	0.78 (0.47 to 1.30)
						1.5 to 4.9 g/day	1.15 (0.78 to 1.69)
						5.0 to 29.9 g/day	1.00 (0.69 to 1.44)
2001 Stolzenberg-Solomon ⁴³	US	Alpha-Tocopherol Beta-Carotene Cancer Prevention Study cohort	1985–1997	27101 Men	Pancreatic cancer	None	1.0
						>0 to 5.3 g/day	1.39 (0.75 to 2.56)
						>5.3 to 13.4 g/day	1.39 (0.75 to 2.56)
						>13.4 to 27.7 g/day	1.24 (0.66 to 2.32)
2002 Isaksson ⁴⁴	Sweden	Swedish Twin Registry	1969–1997	21884 Women/Men	Pancreatic cancer	None	1.00
						1 to 209 g/month	0.89 (0.61 to 1.30)
2009 Heinen ⁴⁵	Netherlands	Netherlands Cohort Study	1986	120852 Women/Men	Pancreatic cancer	Abstainers	1.00
						0.1 to <5 g/day	1.03 (0.74 to 1.42)
						5 to <15 g/day	1.12 (0.79 to 1.57)
						15 to <30 g/day	0.86 (0.58 to 1.28)
2015 Klatsky ¹⁹	US	Multiethnic Northern	1978–2012	124193	Pancreatic	Never drinkers	1.00

		California population (Kaiser Permanente)		Women/Men	cancer	<1 drink/day 1 to 2 drinks/day	0.9 (0.7 to 1.2) 1.1 (0.8 to 1.5)
Lung cancer							
1990 Stemmermann ³⁵	US	American Men of Japanese ancestry residing in Hawaiian island (Oahu)	1965–1989	8006 Men	Lung cancer	0 >0 to <5 oz/month 5 to 14 oz/month 15 to 39 oz/month	1.0 0.75 (0.48 to 1.17) 0.93 (0.59 to 1.47) 1.43 (0.99 to 2.06)
1999 Prescott ⁴⁶	Denmark	Copenhagen City Heart Study	1976–1992	13053 Women 15107 Men	Lung cancer	0 to <1 drinks/wk 1 to 6 drinks/wk 7 to 13 drinks/wk 0 to <1 drinks/wk 1 to 6 drinks/wk 7 to 13 drinks/wk	1.0 0.89 (0.64 to 1.25) 1.00 (0.64 to 1.56) 1.0 0.85 (0.60 to 1.22) 1.01 (0.72 to 1.42)
2002 Djousse ⁴⁷	US	Framingham Study cohort, offspring cohort	1948, 1971	9238 Women/Men 5126 Women 4112 Men	Lung cancer	0 0.1 to 12 g/day 12.1 to 24 g/day	1.0 1.2 (0.7 to 2.1) 1.1 (0.6 to 2.1)
2005 Freudenheim ⁴⁸	US	Pooled cohort(CNBSS, IWHS, NCS, NYSC, NHS)		262432 Women	Lung cancer	None >0 to <5 g/day 5 to <15 g/day 15 to <30 g/day	1.00 0.78 (0.67 to 0.91) 0.81 (0.68 to 0.97) 0.92 (0.74 to 1.13)
		Pooled cohort(ATBC, HPFU, NLCS, NYSC)		137335 Men	Lung cancer	None >0 to <5 g/day 5 to <15 g/day 15 to <30 g/day	1.00 0.86 (0.71 to 1.03) 1.0 (0.84 to 1.20) 0.83 (0.62 to 1.10)

2008 Kabat ²⁶	Canada	Canadian National Breast Screening Study	1980–2000	49654 Women	Lung cancer	Never	1.00	
						>0 to <5g/day	0.94 (0.69 to 1.27)	
						5 to <10 g/day	0.77 (0.52 to 1.13)	
						10 to <20 g/day	0.76 (0.53 to 1.11)	
						20 to <30 g/day	0.81 (0.49 to 1.34)	
2009 Allen ²	UK	Million Women Study	1996–2001	1280296 Women	Lung cancer	Nondrinkers	1.17 (1.12 to 1.23)	
						1 to 2 drinks/wk	1.00	
						3 to 6 drinks/wk	0.91 (0.85 to 0.97)	
						7 to 14 drinks/wk	1.06 (1.00 to 1.13)	
2011 Chao ⁴⁹	US	VITAL Study	2000–2007	66186 Women/Men	Lung cancer	Nondrinkers	1.00	
						>0 to <1 drink/day	1.00 (0.82 to 1.22)	
						Women	>0 to <1 drink/day	0.94 (0.64 to 1.39)
						Men	>0 to <1 drink/day	0.84 (0.62 to 1.15)
2015 Hippisley–Cox ⁴	UK	primary care patients from open cohort study using Qresearch database (EMIS computer system)	1998–2013	Men	Lung cancer	Non-drinkers	1.00	
						<1 unit/day	0.91 (0.87 to 0.95)	
						1–2 units/day	0.92 (0.87 to 0.97)	
2015 Klatsky ¹⁹	US	Multiethnic Northern California population (Kaiser Permanente)	1978–2012	124193 Women/Men	Lung cancer	Never drinkers	1.00	
						<1 drink/day	1.0 (0.9 to 1.2)	
						1 to 2 drinks/day	1.0 (0.8 to 1.2)	
2016 Troche ⁵⁰	US	NIH–AARP Diet and Health Study	1995–2006	492902 Women/Men (198656 Women, 294246 Men)	Lung cancer	None	1.0	
						0.01–0.49 drinks/day	0.92 (0.87 to 0.97)	
						0.5–0.99 drinks/day	0.89 (0.82 to 0.96)	
Breast cancer								
1989	US	Framingham Heart Study	1948	2636 Women	Breast cancer	None	1.0	

Schaatzkin ⁵¹			(32yrs)	(32–64yrs)		0.1 to 1.4 g/day 1.5 to 4.9 g/day	1.0 (0.6 to 1.5) 0.7 (0.4 to 1.1)
1991 Simon ⁵²	US	Tecumseh Community Health Study (TCHS)	1959–1960 (28yrs)	1954 Women	Breast cancer	Never >0 to <1 drink/day 1 to <2 drinks/day	1.0 1.08 (0.64 to 1.82) 1.23 (0.49 to 3.10)
1992 Gapstur ⁵³	US	Iowa Women's Health Study	1986–1989	41837 Women	Breast cancer	0 >0 to <1.5 g/day 1.5 to 4.9 g/day 5.0 to 14.9 g/day	1.0 1.18 (0.86 to 1.61) 1.20 (0.93 to 1.56) 1.25 (0.93 to 1.68)
1995 van den Brandt ⁵⁴	Netherlands	Netherlands Cohort Study	1986–1989 (3.3yrs)	62573 Women (55–69yrs)	Breast cancer	Nondrinkers >0 to <5 g/day 5 to 14 g/day 15 to 29 g/day	1.00 1.30 (0.96 to 1.75) 1.29 (0.89 to 1.85) 1.28 (0.81 to 2.03)
1999 Garland ⁵⁵	US	Nurses' Health Study II	1989 (6yrs)	116671 Women (25–42yrs)	Breast cancer	Nondrinker >0 to 1.5 g/day >1.5 to 5 g/day >5 to 10 g/day >10 to 20 g/day	1.00 0.96 (0.72 to 1.28) 0.78 (0.59 to 1.62) 1.01 (0.72 to 1.41) 1.12 (0.77 to 1.63)
1999 Zhang ⁵⁶	US	Framingham Original Cohort & Offspring Cohort	1948–1993, 1971–1993	5048 Women	Breast cancer	Nondrinker 0.1 to <5.0 g/day 5.0 to <15 g/day	1.00 0.80 (0.60 to 1.10) 0.70 (0.50 to 1.10)
2000 Rohan ⁵⁷	Canada	Canadian National Breast Screening Study (NBSS)	1980–1993	56837 Women (40–59yrs)	Breast cancer	0 >0 to 10 g/day >10 to 20 g/day	1.0 1.01 (0.84 to 1.22) 1.16 (0.91 to 1.47)

						>20 to 30 g/day	1.27 (0.91 to 1.78)
2001 Feigelson ⁵⁸	US	American Cancer society Cancer Prevention Study II Nutrition Cohort (CPS-II Nutrition Cohort)	1982–1996	242010 Women	Breast cancer	None	1.0
						<0.25 drinks/day	1.1 (0.88 to 1.3)
						0.26 to <1 drink/day	1.2 (1.0 to 1.4)
						1 to <2 drinks/day	1.3 (1.1 to 1.6)
2002 Chen ⁵⁹	US	Nurses' Health Study	1980–1994	44186 Women	Breast cancer (invasive tumors)	None	1.00
						0.1 to 4.9 g/day	1.07 (0.95 to 1.20)
						5.0 to 9.9 g/day	0.99 (0.83 to 1.18)
						10 to 19.9 g/day	1.22 (1.06 to 1.42)
2002 Horn– Ross ⁶⁰	US	California Teachers Study cohort	1995–1998	111526 Women	Breast cancer	Nondrinkers	1.0
						<5 g/day	0.9 (0.7 to 1.2)
						5 to 9 g/day	0.9 (0.7 to 1.2)
						10 to 14 g/day	1.2 (0.9 to 1.6)
						15 to 19 g/day	1.0 (0.8 to 1.4)
2003 Feigelson ⁶¹	US	American Cancer society Cancer Prevention Study II Nutrition Cohort (CPS-II Nutrition Cohort)	1992–1998	66561 Women	Breast cancer	None	1.00
						0.1 to <5 g/day	1.00 (0.88 to 1.15)
						5 to <10 g/day	0.94 (0.77 to 1.16)
						10 to <15 g/day	1.18 (0.96 to 1.46)
2004 Dumeaux ⁶²	Norway	Norwegian Women and Cancer Study	1991–2001	86948 Women (30–70yrs)	Breast cancer	None	1.00
						0.1 to 4.9 g/day	1.24 (1.06 to 1.44)
						5.0 to 9.9 g/day	1.35 (1.11 to 1.64)
2004 Horn– Ross ⁶³	US	California Teachers Study cohort	1995–2001	103460 Women (postmenopau sal)	Breast cancer	Nondrinkers	1.00
						<5 g/day	1.03 (0.86 to 1.24)
						5–9 g/day	1.04 (0.86 to 1.27)
						10–14 g/day	1.08 (0.88 to 1.33)

2004 Sellers ⁶⁴	US	Iowa Women's Health Study	1986–1999	33552 Women (55–69yrs)	Breast cancer	0 >0 to 4 g/day	1.00 1.07 (0.95 to 1.21)
2005 Suzuki ⁶⁵	Sweden	Swedish Mammography Cohort	1987–2004	51847 Women	Breast cancer (invasive tumors)	Nondrinkers >0 to <3.4 g/day 3.4 to 9.9 g/day	1.00 1.08 (0.94 to 1.25) 1.10 (0.94 to 1.29)
2006 Mellekjar ⁶⁶	Denmark	Danish Prospective Cohort Study	1993–2002	23788 Women	Breast cancer	Abstainers >0 to 12 g/day	0.94 (0.56 to 1.58) 1.10 (1.04 to 1.16)
2006 Stolzenberg–Solomon ⁶⁷	US	Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial	1993–2001	25400 Women (55–74yrs)	Breast cancer	0 to 0.01 g/day >0.01 to 0.43 g/day >0.43 to 1.39 g/day >1.39 to 7.62 g/day	1.00 1.21 (0.94 to 1.57) 1.18 (0.92 to 1.51) 0.94 (0.72 to 1.22)
2007 Tjonneland ⁶⁸	Europe	European Prospective Investigation into Cancer and Nutrition (EPIC)	1993/2004 (6.4yrs)	274688 Women	Breast cancer (invasive tumors)	Abstainers >0 to 1.5 g/day >1.5 to 4.7 g/day >4.7 to 10 g/day >10 to 19 g/day	1.01 (0.91 to 1.13) 1.00 0.98 (0.89 to 1.09) 0.97 (0.88 to 1.08) 1.07 (0.96 to 1.19)
2007 Zhang ⁶⁹	US	Women's Health Study (US female health professionals)	1992–2004	38454 Women	Breast cancer (invasive and in situ tumors)	None 0.1 to 4.9 g/day 5.0 –9.9 g/day 10.0 to 14.9 g/day 15.0 to 29.9 g/day	1.00 1.02 (0.90 to 1.15) 1.13 (0.95 to 1.34) 1.14 (0.92 to 1.40) 1.16 (0.92 to 1.40)
					Breast cancer (invasive tumors)	None 0.1 to 4.9 g/day 5.0 –9.9 g/day 10.0 to 14.9 g/day	1.00 1.00 (0.88 to 1.15) 1.03 (0.84 to 1.25) 1.16 (0.92 to 1.47)

						15.0 to 29.9 g/day	1.19 (0.93 to 1.53)
2008 Kabat ²⁶	Canada	Canadian National Breast Screening Study	1980–2000	49654 Women	Breast cancer	never	1.00
						>0 to <5g/day	1.00 (0.90 to 1.12)
						5 to <10 g/day	0.98 (0.86 to 1.13)
						10 to <20 g/day	1.07 (0.93 to 1.23)
						20 to <30 g/day	1.08 (0.89 to 1.32)
2009 Allen ²	UK	Million Women Study	1996–2001	1280296 Women	Breast cancer	Nondrinkers	1.00 (0.97 to 1.03)
						3 to 6 drinks/wk	1.08 (1.05 to 1.10)
						7 to 14 drinks/wk	1.13 (1.10 to 1.16)
2009 Lew ⁷⁰	US	NIH–AARP Diet and Health Study	1995–2003	184418 Women	Breast cancer	0	1.00
						>0 to 5 g/day	1.04 (0.97 to 1.10)
						>5 to 10 g/day	1.04 (0.93 to 1.16)
						>10–20 g/day	1.13 (1.02 to 1.25)
2010 Li ⁷¹	US	Women's Health Initiative to observational study (WHI–OS)	1993–2005	87724 Women	Breast cancer	Nondrinkers	1.00
						>0 to <0.5 drinks/wk	1.02 (0.87 to 1.18)
						0.5 to 0.9 drinks/wk	1.05 (0.85 to 1.28)
						1.0 to 3.9 drinks/wk	1.10 (0.94 to 1.30)
						4.0 to 6.9 drinks/wk	1.12 (0.91 to 1.36)
						7.0 to 13.9 drinks/wk	1.27 (1.05 to 1.53)
2011 Chen ⁷²	US	Nurses' Health Study	1980–2008	105986 Women (30–55yrs)	Breast cancer (invasive tumors)	Nondrinkers	1.00
						0.1 to 4.9 g/day	1.07 (1.00 to 1.14)
						5 to 9.9 g/day	1.15 (1.06 to 1.26)
2011 Kawai ⁷³	Japan	The Miyagi Cohort Study	1990–2003	19227 Women	Breast cancer	Never	1.00
						< 5.0 g/day	1.02 (0.72 to 1.46)
						5 to <15 g/day	1.21 (0.71 to 2.08)

2013 Liu ⁷⁴	US	Nurses' Health Study II	1989–2009	91005 Women (25–44yrs)	Breast cancer	0 0.1 to 4.9 g/day 5.0 to 14.9 g/day	1.00 1.08 (0.94 to 1.23) 1.11 (0.94 to 1.32)
2014 Falk ⁷⁵	US	Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Cohort	1993–2009	54562 Women (55–74yrs)	Breast cancer	Never <0.5 drink/wk 0.5 to <1 drink/wk 1 to <7 drinks/wk	1.00 1.15 (0.97 to 1.36) 1.25 (1.03 to 1.53) 1.26 (1.07 to 1.49)
2014 Park ⁷⁶	US	Multiethnic Cohort in California and Hawaii	1993–2007 (mean 12.4y rs)	85089 Women	Breast cancer	0 0.1 to 4.9 g/day 5 to 9.9 g/day 10 to 14.9 g/day	1.00 0.98 (0.91 to 1.07) 1.23 (1.06 to 1.42) 1.21 (1.00 to 1.45)
2015 Chhim ⁷⁷	France	SU.VI.MAX	1994–2007	3771 Women	Breast cancer	0 to <3 g/day 3 to 12 g/day	1.00 1.28 (0.82 to 2.00)
2015 Fagherazzi ⁷⁸	France	French E3N–EPIC cohort	1993–2008	66481 Women	Breast cancer	None 10 to 20 g/day	1.00 1.02 (0.97 to 1.07)
2015 Hippisley– Cox ⁴	UK	primary care patients from open cohort study using Qresearch database (EMIS computer system)	1998–2013	Women	Breast cancer	Non-drinkers <1 unit/day 1–2 units/day	1.00 1.05 (1.03 to 1.08) 1.11 (1.07 to 1.15)
2015 Klatsky ¹⁹	US	Multiethnic Northern California population (Kaiser Permanente)	1978–2012	124193 Women/Men	Breast cancer	Never drinkers <1 drink/day 1 to 2 drinks/day	1.00 1.1 (1.0 to 1.2) 1.2 (1.1 to 1.4)
2015 Shin ⁷⁹	Sweden	Swedish Women's Lifestyle and Health study	1991–2009	45233 Women	Breast cancer	0 0.1 to 5 g/day 5.1 to 15 g/day	1.00 1.03 (0.89 to 1.20) 1.16 (0.99 to 1.36)
2016 Nitta ⁸⁰	Japan	Japan Collaborative Cohort	1988–2009	38610 Women	Breast cancer	0	1.00

Study (JACC)						0.1 to 4.9 g/day	1.25 (0.64 to 2.41)
						5.0 to 14.9 g/day	0.49 (0.15 to 1.56)
Endometrial cancer							
1993 Gapstur ⁸¹	US	Iowa Women's Health Study	1986–1990	25170 Women	Endometrial cancer	0	1.0
						>0 to <4.0 g/day	0.7 (0.5 to 1.1)
1999 Terry ⁸²	Sweden	Swedish Twin Registry	1967–1992	11659 Women	Endometrial cancer	None	1.0
						Up to 2 drinks/wk	1.7 (1.03 to 2.82)
						2 to 4 drinks/wk	1.2 (0.6 to 2.4)
2007 Loerbroks ⁸³	Netherlands	Netherlands Cohort Study	1986–1997 (11.3yrs)	62573 Women (55–69yrs)	Endometrial cancer	No	1.00
						0.1 to 4 g/day	1.09 (0.78 to 1.52)
						5 to 14 g/day	0.95 (0.62 to 1.45)
						15 to 29 g/day	0.94 (0.52 to 1.69)
2008 Kabat ²⁶	Canada	Canadian National Breast Screening Study	1980–2000	49654 Women	Endometrial cancer	Never	1.00
						>0 to <5g/day	1.15 (0.88 to 1.51)
						5 to <10 g/day	1.00 (0.71 to 1.41)
						10 to <20 g/day	1.21 (0.86 to 1.68)
						20 to <30 g/day	1.34 (0.85 to 2.12)
2008 Setiawan ⁸⁴	US	Multiethnic Cohort Study in California and Hawaii	1993–2002 (ave8.3yrs)	41574 Women	Endometrial cancer	Nondrinkers	1
						<1 drink/day	1.01 (0.77 to 1.33)
						1 to <2 drinks/day	1.09 (0.62 to 1.93)
2009 Allen ²	UK	Million Women Study	1996–2001	1280296 Women	Endometrial cancer	Nondrinkers	1.06 (1.00 to 1.12)
						3 to 6 drinks/wk	0.99 (0.92 to 1.05)
						7 to 14 drinks/wk	0.90 (0.83 to 0.97)
2009 Friberg ⁸⁵	Sweden	Swedish Mammography	1987–1997	61226 Women	Endometrial	Nondrinkers	1.00

Cohort					cancer	>0 to <3.4 g/day	1.01 (0.85 to 1.20)
						3.4 to 9.9 g/day	0.95 (0.75 to 1.19)
2011 Yang ⁸⁶	US	NIH–AARP Diet and Health study	1995–2006	114414 Women	Endometrial cancer	Nondrinkers	1.00
						>0 to <12 g/day	0.97 (0.87 to 1.09)
2014 Je ⁸⁷	US	Nurses' Health Study	1980–2010	68067 Women (34–59yrs)	Endometrial cancer	Nondrinkers	1.00
						0.1 to 4.9 g/day	0.78 (0.66 to 0.94)
						5 to 14.9 g/day	0.88 (0.71 to 1.09)
						15 to 29.9 g/day	0.83 (0.61 to 1.14)
Ovarian cancer							
2007 Chang ⁸⁸	US	California Teachers Study cohort	1995–2003	90371 Women	Ovarian cancer	None	1.00
						>0 to <10.0 g/day	1.04 (0.76 to 1.42)
						10.0 to <20.0 g/day	1.47 (1.06 to 2.03)
2008 Kabat ²⁶	Canada	Canadian National Breast Screening Study	1980–2000	49654 Women	Ovarian cancer	Never	1.00
						>0 to <5g/day	0.90 (0.63 to 1.29)
						5 to <10 g/day	1.33 (0.89 to 1.96)
						10 to <20 g/day	0.85 (0.54 to 1.32)
						20 to <30 g/day	1.50 (0.88 to 2.56)
2008 Tworoger ⁸⁹	US	Nurses' Health Study (NHS)	1976–2004	110454 Women	Ovarian cancer (epithelial)	<0.1 g/day	1.00
						0.1 to 4.9 g/day	1.05 (0.83 to 1.33)
						5.0 to 14.9 g/day	0.99 (0.75 to 1.30)
2009 Allen ²	UK	Million Women Study	1996–2001	1280296 Women	Ovarian cancer	Nondrinkers	0.94 (0.88 to 1.01)
						1 to 2 drinks/wk	1.00
						3 to 6 drinks/wk	0.89 (0.83 to 0.95)
						7 to 14 drinks/wk	0.97 (0.90 to 1.05)
2015 Klatsky ¹⁹	US	Multiethnic Northern	1978–2012	124193	Ovarian cancer	Never drinkers	1.0

		California population (Kaiser Permanente)		Women/Men		<1 drink/day 1 to 2 drinks/day	1.2 (0.9 to 1.6) 1.2 (0.8 to 1.8)
Cervix and uterus cancer							
2009 Allen ²	UK	Million Women Study	1996–2001	1280296 Women	Cervix cancer	Nondrinkers 1 to 2 drinks/wk 3 to 6 drinks/wk 7 to 14 drinks/wk	1.31 (1.10 to 1.55) 1.00 1.04 (0.86 to 1.27) 0.98 (0.79 to 1.22)
2015 Klatsky ¹⁹	US	Multiethnic Northern California population (Kaiser Permanente)	1978–2012	124193 Women/Men	Cervix cancer	Never drinkers <1 drink/day 1 to 2 drinks/day	1.00 1.0 (0.8 to 1.3) 1.0 (0.8 to 1.4)
Prostate cancer							
1990 Stemmermann ³⁵	US	American Men of Japanese ancestry residing in Hawaiian island (Oahu)	1965–1989	8006 Men	Prostate cancer	0 >0 to <5 oz/month 5 to 14 oz/month 15 to 39 oz/month	1.00 0.87 (0.61 to 1.25) 0.86 (0.57 to 1.29) 1.02 (0.69 to 1.52)
1999 Breslow ⁹⁰	US	National Health and Nutrition Examination Survey (NHANES I)	1971–1992	5766 Men	Prostate cancer	Nondrinkers >0 to 1 drinks/wk 2 to 7 drinks/wk 8 to 14 drinks/wk	1.00 0.97 (0.67 to 1.41) 0.88 (0.64 to 1.21) 0.96 (0.61 to 1.50)
1999 Parker ⁹¹	US	NCI's SEER program	1980-1995	1177 men	prostate cancer	none <22 g/week 23-92 g/week	1.0 1.3 (0.7 - 2.5) 2.4 (1.3 - 4.2)
1999 Schuurman ⁹²	Netherlands	Netherlands Cohort Study	1986 (6.3yrs)	58279 Men (aged55–69)	Prostate cancer	Nondrinkers 0.1 to 4 g/day	1.0 1.1 (0.8 to 1.5)

						5 to 14 g/day	0.9 (0.7 to 1.3)
						15 to 29 g/day	1.1 (0.8 to 1.4)
2000 Ellison ⁹³	Canada	Nutrition Canada Survey (NCS)	1970–1993	3400 Men (50–84yrs)	Prostate cancer	0	1.00
						>0 to 9.9 mL/day	0.96 (0.63 to 1.47)
						10.0 to 24.9 mL/day	0.85 (0.50 to 1.45)
2001 Sesso ⁹⁴	US	Harvard alumni	1988–1993	7612 Men (mean 66yrs)	Prostate cancer	almost never	1.00
						1 drink/month to <3 drink/wk	1.33 (0.88 to 2.01)
						3 drinks/wk to <1 drink/day	1.65 (1.12 to 2.44)
2002 Albertsen ⁹⁵	Denmark	Copenhagen Center for Prospective Population Studies (Copenhagen City Heart Study, Copenhagen Male Study, Copenhagen County Center for Preventive Medicine)	1976–1994(mean 12.3yrs)	12989 Men (20–98yrs)	Prostate cancer	<1 drink/wk	1.00
						1 to 6 drinks/wk	0.90 (0.61 to 1.34)
						7 to 13 drinks/wk	0.86 (0.57 to 1.29)
						14 to 20 drink/wk	0.91 (0.58 to 1.44)
2004 Platz ⁹⁶	US	Health Professionals Follow-up Study	1986–1998	47843 Men (40–75yrs)	Prostate cancer	0	1.00
						0.1 to 4.9 g/day	0.99 (0.87 to 1.11)
						5.0 to 14.9 g/day	1.05 (0.94 to 1.18)
						15.0 to 29.9 g/day	1.13 (0.98 to 1.31)
2006 Weinstern ⁹⁷	US	Alpha-Tocopherol Beta-Carotene Cancer Prevention Study cohort	1985–2002	29133 Men	Prostate cancer	Nondrinkers	1
						≤3.7 g/day	0.98 (0.8 to 1.2)
						>3 to ≤10 g/day	0.96 (0.78 to 1.17)
						>10 to ≤18.7 g/day	1.03 (0.84 to 1.26)
						>18.7 to ≤32.2 g/day	0.90 (0.83 to 1.11)
2006 Velicer ⁹⁸	US	VITAL Study	2000–2004	34565 Men	Prostate cancer	None or <1 drink/mo	1
						<1/mo to <4drinks/mo	1.26 (1.05 to 1.5)

						5 drinks/mo to 2/day	1.20 (0.99 to 1.46)
2007 Sutcliffe ⁹⁹	US	Health Professionals Follow-up Study (HPFS)	1986–2002	45433 Men	Prostate cancer	No alcohol consumption	1.00
						0.01 to 1.31 g/day	0.90 (0.74 to 1.09)
						1.32 to 2.41 g/day	1.02 (0.85 to 1.22)
						2.42 to 7.03 g/day	1.12 (0.97 to 1.29)
						7.04 to 16.4 g/day	1.16 (1.01 to 1.32)
2009 Gong ¹⁰⁰	US	Prostate Cancer Prevention Trial		2129 Men	Prostate cancer	No alcohol consumption	1.00
						>0 to < 3g/day	0.97 (0.85 to 1.11)
						3 to <15 g/day	0.98 (0.85 to 1.12)
						15 to <30 g/day	1.05 (0.89 to 1.23)
2010 Chao ¹⁰¹	US	California Men's Health Study (CMHS)	2002–2007	65972 Men	Prostate cancer	Nondrinker	1.0
						<1 drink/day	0.98 (0.86 to 1.11)
						1 to <3 drinks/day	0.98 (0.84 to 1.15)
2010 Watters ¹⁰²	US	NIH–AARP Diet and Health Study	1995–2005	294707 Men (50–71yrs)	Prostate cancer	Nondrinkers	1.00
						>0 to <1 drinks/day	1.06 (1.01 to 1.10)
2015 Klatsky ¹⁹	US	Multiethnic Northern California population (Kaiser Permanente)	1978–2012	124193 Women/Men	Prostate cancer	Never drinkers	1.00
						<1 drink/day	1.1 (0.9 to 1.2)
						1 to 2 drinks/day	1.1 (1.0 to 1.3)
Renal cell carcinoma							
2005 Mahabir ¹⁰³	US	Alpha–Tocopherol BetaCarotene (ATBC) Cancer Prevention Study	1985–1999	27111 Men	Renal cell carcinoma	0 to 2.5 g/day	1.00
						2.6 to 11.0 g/day	0.91 (0.62 to 1.33)
						11.1 to 25.6 g/day	0.94 (0.64 to 1.38)
2007 Setiawan ¹⁰⁴	US	Hawaii–Los Angeles Multiethnic Cohort	1993–2002 (8.3yrs)	85964 Women	Renal cell carcinoma	None	1.00
						>0 to <4.2 g/day	0.75 (0.45 to 1.24)
				75162 Men		None	1.00
						>0 to <14.5 g/day	0.84 (0.61 to 1.15)

2008 Schouten ¹⁰⁵	Netherlands	NLCS on Diet and Cancer	1986–1997	5044 Women/Men (2415 Women, 2629 Men)	Renal cell carcinoma	No alcohol intake	1.00			
						0.1 to 4.9 g/day	0.71 (0.50 to 1.00)			
						5.0 to 14.9 g/day	0.66 (0.46 to 0.94)			
2009 Allen ²	UK	Million Women Study	1996–2001	1280296 Women	Renal cell carcinoma	Nondrinkers	1.12 (1.00 to 1.26)			
						1 to 2 drinks/wk	1.00			
						3 to 6 drinks/wk	1.01 (0.89 to 1.14)			
						7 to 14 drinks/wk	0.93 (0.80 to 1.07)			
2012 Macleod ¹⁰⁶	US	VITAL study	2000–2009	77260 Women/Men (50–76yrs)	Renal cell carcinoma	Nondrinkers	1.00			
						1 drink/day	0.94 (0.71 to 1.26)			
						2 drinks/day	0.76 (0.47 to 1.20)			
2015 Karami ¹⁰⁷	US	Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO)	1993–2001	107998 Women/Men	Renal cell carcinoma	None	1			
						>0 to 1.75 g/day	0.98 (0.75 to 1.29)			
						>1.75 to 9.75 g/day	0.77 (0.58 to 1.02)			
						None	1			
				Women		>0 to 1.75 g/day	0.86 (0.58 to 1.28)			
						>1.75 to 9.75 g/day	0.51 (0.30 to 0.88)			
						Men		None	1	
								>0 to 1.75 g/day	1.09 (0.76 to 1.58)	
		>1.75 to 9.75 g/day	0.93 (0.66 to 1.31)							
2015 Klatsky ¹⁹	US	Multiethnic Northern California population (Kaiser Permanente)	1978–2012	124193 Women/Men	Renal cell carcinoma	Never drinkers	1.00			
						<1 drink/day	1.0 (0.7 to 1.4)			
						1 to 2 drinks/day	0.9 (0.6 to 1.4)			
Bladder cancer										
1993 Chyou ¹⁰⁸	Japan	American Men of Japanese ancestry residing in Hawaiian island	1965~	7995 Men	Bladder cancer	0	1.0			
						<15 g/day	1.31 (0.8 to 2.13)			

2001 Zeegers ¹⁰⁹	Netherland	Netherlands Cohort Study	1986–1992	62573 Women	Bladder cancer	No alcohol	1.0
				58279 Men		<5 g/day	0.97 (0.56 to 1.69)
						No alcohol	1.0
						<5 g/day	1.49 (1.00 to 2.21)
						5–<15 g/day	1.52 (1.04 to 2.21)
						15–<30 g/day	1.16 (0.78 to 1.71)
2009 Allen ²	UK	Million Women Study	1996–2001	1280296 Women	Bladder cancer	Nondrinkers	1.06 (0.94 to 1.21)
						3 to 6 drinks/wk	1.05 (0.92 to 1.21)
						7 to 14 drinks/wk	0.91 (0.77 to 1.07)
2015 Klatsky ¹⁹	US	Multiethnic Northern California population (Kaiser Permanente)	1978–2012	124193 Women/Men	Bladder cancer	Never drinkers	1.00
						<1 drink/day	1.2 (0.9 to 2.6)
						1 to 2 drinks/day	1.3 (0.9 to 1.7)
Thyroid cancer							
2005 Navarro Silvera ¹¹⁰	Canada	Canadian National Breast Screening Study (NBSS)	~2000	89835 Women	Thyroid cancer	None	1.0
						1 to 3 g/day	1.17 (0.68 to 2.01)
						3 to 10 g/day	0.67 (0.36 to 1.22)
2009 Allen ²	UK	Million Women Study	1996–2001	1280296 Women	Thyroid cancer	Nondrinkers	1.10 (0.91 to 1.33)
						3 to 6 drinks/wk	0.90 (0.74 to 1.10)
						7 to 14 drinks/wk	0.70 (0.55 to 0.91)
2009 Meinhold ¹¹¹	US	NIH–AARP Diet and Health Study	1995–1996 (7.5yrs, median)	490159 Women/Men (50–71yrs)	Thyroid cancer	Nondrinkers	1.00
						>0 to <1 drink/wk	0.87 (0.66 to 1.13)
						1 to 6 drinks/wk	0.87 (0.66 to 1.16)
						1 to 2 drinks/day	0.67 (0.44 to 1.00)
				198058 Women		Nondrinkers	1.00
						>0 to <1 drink/wk	0.81 (0.58 to 1.14)

				292101 Men		1 to 6 drinks/wk 1 to 2 drinks/day Nondrinkers >0 to <1 drink/wk 1 to 6 drinks/wk 1 to 2 drinks/day	0.84 (0.57 to 1.24) 0.55 (0.31 to 0.95) 1.00 0.97 (0.62 to 1.51) 0.90 (0.59 to 1.38) 0.69 (0.40 to 1.20)
2010 Meinhold ¹¹²	US	US Radiologic Technologists Study	1983–2006	69506 Women	Thyroid cancer	Nondrinker <1 drink/wk 1–6 drinks/wk	1.0 0.86 (0.62 to 1.20) 0.86 (0.60 to 1.23)
				21207 Men		Nondrinker <1 drink/wk 1–6 drinks/wk	1.0 1.03 (0.45 to 2.38) 0.62 (0.25 to 1.54)
2012 Kabat ¹¹³	US	Women's Health Initiative	1993–2002	159340 Women (50–79yrs)	Thyroid cancer	Nondrinkers >0 to <1 drink/wk 1 to <7 drinks/wk	1.00 0.93 (0.69 to 1.25) 0.95 (0.72 to 1.25)
2015 Klatsky ¹⁹	US	Multiethnic Northern California population (Kaiser Permanente)	1978–2012	124193 Women/Men	Thyroid cancer	Never drinkers <1 drink/day 1 to 2 drinks/day 1 to <4 g/day	1.00 1.0 (0.6 to 1.6) 0.6 (0.3 to 1.1) 1.01 (0.76 to 1.36)
Hematologic malignancy							
1999 Chiu ¹¹⁴	US	Iowa Women's Health Study	1987–1992	41837 Women	Hematologic malignancy (NHL)	Nondrinkers ≤3.4 g/day	1.0 0.78 (0.51 to 1.21)
2007 Lim ¹¹⁵	US	NIH–AARP Diet and Health Study	1995–2000	465858 Women/Men	Hematologic malignancy (Hodgkin's lymphoma)	None 0.1 to 1.9 drinks/wk 2 to 7 drinks/wk 7.1 to 14 drinks/wk	1.00 0.73 (0.39 to 1.36) not shown 0.76 (0.37 to 1.58)

2009 Allen ²	UK	Million Women Study	1996–2001	1280296 Women	Hematologic malignancy (Non–Hodgikin's Lymphoma)	Nondrinkers 1 to 2 drinks/wk 3 to 6 drinks/wk 7 to 14 drinks/wk 3 to 6 drinks/wk	1.03 (0.95 to 1.12) 1.00 1.02 (0.94 to 1.11) 0.86 (0.78 to 0.96) 0.93 (0.81 to 1.07)
2009 Klatsky ¹¹⁶	US	members of comprehensive pre–paid health care programme in SF Bay area	1978–2006 (16.9yrs)	126293 Women/Men (mean41.0yrs) 70598 Women 55695 Men	Hematologic malignancy	never to <1 drink/month >0 to <1 drink/day 1 to 2 drinks/day never to <1 drink/month >0 to <1 drink/day 1 to 2 drinks/day never to <1 drink/month >0 to <1 drink/day 1 to 2 drinks/day	1.00 1.0 (0.90 to 1.20) 0.9 (0.70 to 1.00) 1.00 0.9 (0.8 to 1.2) 0.9 (0.7 to 1.2) 1.00 1.1 (0.9 to 1.4) 0.9 (0.7 to 1.1)
2010 Chang ¹¹⁷	US	California Teachers Study	1995–2007	102721 Women	Hematologic malignancy (B–cell NHL) Hematologic malignancy (multiple myeloma)	Nondrinkers 0.1 to <5 g/day 5 –< 10g/day Nondrinkers 0.1 to <10 g/day	1.00 1.16 (0.88 to 1.54) 0.98 (0.73 to 1.31) 1.00 0.65 (0.39 to 1.09)
2010 Troy ¹¹⁸	US	PLCO Cancer Screening Trial	1993–2006	142982 Women/Men (55–74yrs)	Hematologic malignancy (NHL)	0 to <1 drink/wk 1 to 3 drinks/wk 4 to 13 drinks/wk	1.00 1.08 (0.85 to 1.37) 0.88 (0.68 to 1.14)
2012 Gapstur ¹¹⁹	US	Cancer Prevention Study II Nutrition cohort	1992–2007	143124 Women/Men (50–74yrs) 74,785 Women	Hematologic malignancy (NHL)	Nondrinkers >0 to <1 drink/day 1 to 2 drinks/day Nondrinkers	1.00 0.93 (0.83 to 1.03) 0.91 (0.78 to 1.06) 1.00

				68,339 Men		>0 to <1 drink/day 1 to 2 drinks/day Nondrinkers	0.95 (0.81 to 1.10) 0.87 (0.67 to 1.14) 1.00
						>0 to <1 drink/day 1 to 2 drinks/day	0.90 (0.78 to 1.05) 0.90 (0.75 to 1.09)
2015 Klatsky ¹⁹	US	Multiethnic Northern California population (Kaiser Permanente)	1978–2012	124193 Women/Men	Hematologic cancer	Never drinkers <1 drink/day 1 to 2 drinks/day	1.0 1.1 (0.9 to 1.2) 1.0 (0.8 to 1.2)
Malignant melanoma							
2003 Freedman ¹²⁰	US	US Radiologic Technologists (USRT) Study	1983–1998	68588 Women/Men	Melanoma	Never <1 to 6 drinks/wk 7 to 14 drinks/wk	1.0 1.2 (0.8 to 1.8) 1.4 (0.8 to 2.5)
				54045 Women		Never <1 to 6 drinks/wk 7 to 14 drinks/wk	1.0 1.2 (0.7 to 1.9) 1.7 (0.9 to 3.1)
				14543 Men		Never <1 to 6 drinks/wk 7 to 14 drinks/wk	1.0 1.5 (0.7 to 3.4) 0.9 (0.2 to 3.0)
2014 Kubo ¹²¹	US	Women's Health Initiative to observational study (WHI–OS)	1993–2010	59575 Women	Melanoma	Nondrinkers <1 drink/wk 1 to <7 drinks/wk	1.00 1.10 (0.74 to 1.66) 1.40 (0.95 to 2.06)
					Non–melanoma	Nondrinkers <1 drink/wk 1 to <7 drinks/wk	1.00 1.08 (0.98 to 1.20) 1.15 (1.05 to 1.27)
2015 Klatsky ¹⁹	US	Multiethnic Northern California population (Kaiser Permanente)	1978–2012	124193 Women/Men	Melanoma	Never drinkers <1 drink/day 1 to 2 drinks/day	1.0 1.6 (1.2 to 2.1) 1.9 (1.4 to 2.6)

S2 Table. General characteristics of the studies included in the final analysis to cancer mortality

Study	Country	Cohort	Enroll year	Population	Cancer type	Alcohol consumption amount (baseline)	RR (95% CI)
Oral cavity, pharyngeal cancer mortality							
1988 Garfinkel ¹²²	US	American Cancer Society's study	1959–1972	581321 Women	Oral cavity cancer mortality	None	1.00
						1 drink/day	0.40 (0.17 to 0.95)
						2 drinks/day	1.02 (0.54 to 1.94)
2010 Kim ¹²³	Korea	Korea National Health Insurance Corporation	2000–2005	919199 Men	Lip, oral cavity cancer mortality	Nondrinker	1
						1.0 to 14.9 g/day	1.7 (0.94 to 3.05)
						15.0 to 29.9 g/day	0.82 (0.38 to 1.80)
Esophageal cancer mortality							
1988 Garfinkel ¹²²	US	American Cancer Society's study	1959–1972	581321 Women	Esophageal cancer mortality	None	1.00
						1 drink/day	1.37 (0.81 to 2.30)
						2 drinks/day	1.61 (0.94 to 2.77)
1990 Boffetta ¹²⁴	US	American Cancer Society	1959–1972	276802 Men	Esophageal cancer mortality	Nondrinkers	1.00
						1 drink/day	1.37 (0.81 to 2.30)
						2 drinks/day	1.61 (0.94 to 2.77)
2005 Sakata ¹²⁵	Japan	JACC Study	1988–1994	46465 Men	Esophageal cancer mortality	Nondrinkers	1
						<1.0 units/day	1.47 (0.28 to 7.68)
						1.0–1.9 units/day	1.58 (0.65 to 3.86)
2010 Kim ¹²³	Korea	Korea National Health Insurance Corporation	2000–2005	919199 Men	Esophageal cancer mortality	Nondrinkers	1
						1.0 to 14.9 g/day	1.23 (0.82 to 1.85)
						15.0 to 29.9 g/day	1.43 (0.92 to 2.22)
2013 Shen ¹²⁶	Hong Kong	18 Elderly Health Centers of the Hong Kong Government Department of Health	1998–2012	66820 Women/Men	Esophageal cancer mortality	Never	1
						Social (<1/wk)	0.95 * 0.88 to 1.03)
						Wkly social (<10g/day)	1.12 (0.91 to 1.38)
						Moderate(≤30g/day for	1.11 (0.98 to 1.27)

				44140 Women		Men, ≤20g/day for Women) Never	1
						Social (<1/wk)	2.20 (0.96 to 5.06)
						Wkly social (<10g/day)	NA
						Moderate(≤30g/day for Men, ≤20g/day for Women)	2.62 (0.35 to 19.60)
				22680 Men		Never	1
						Social (<1/wk)	1.00 (0.47 to 2.14)
						Wkly social (<10g/day)	0.80 (0.11 to 6.01)
						Moderate(≤30g/day for Men, ≤20g/day for Women)	2.94 (1.42 to 6.07)
Stomach cancer mortality							
2010 Kim ¹²³	Korea	Korea National Health Insurance Corporation	2000–2005	422194 Women	Stomach cancer mortality	Nondrinkers	1
						1.0 to 14.9 g/day	0.65 (0.44 to 0.98)
						15.0 to 29.9 g/day	1.48 (0.85 to 2.57)
				919199 Men		Nondrinkers	1
						1.0 to 14.9 g/day	0.96 (0.83 to 1.11)
						15.0 to 29.9 g/day	1.00 (0.85 to 1.18)
2013 Shen ¹²⁶	HongKong	18 Elderly Health Centers of the Hong Kong Government Department of Health	1998–2012	66820 Women/Men(22680 Men, 44140 Women)	Stomach cancer mortality	Never	1
						Social (<1/wk)	0.73 (0.50 to 1.05)
						Wkly social (<10g/day)	0.55 (0.17 to 1.73)
						Moderate (≤30g/day for Men, ≤20g/day for Women)	1.18 (0.71 to 1.95)
				44140 Women		Never	1
						Social (<1/wk)	0.96 (0.50 to 1.85)
						Wkly social (<10g/day)	NA

				22680 Men		Moderate (≤ 30 g/day for Men, ≤ 20 g/day for Women) Never Social (< 1 /wk) Wkly social (< 10 g/day) Moderate (≤ 30 g/day for Men, ≤ 20 g/day for Women)	NA 1 0.64 (0.41 to 1.00) 0.61 (0.19 to 1.94) 1.21 (0.72 to 2.04)
Colorectal cancer mortality							
1997 Camargo ¹²⁷	US	Physicians' Health Study	1981–1993	22071 Men	Colorectal cancer mortality	0 1 to 6 drinks/wk	1 0.98 (0.56 to 1.72)
1997 Thun ¹²⁸	US	Cancer Prevention Study II	1982–1991	230552 Women	Colorectal cancer mortality	0 less than daily	1 0.8 (0.7 to 1.0)
				226871 Men		0 less than daily 1 drink/day	1 1.0 (0.9 to 1.3) 1.0 (0.8 to 1.3)
2010 Kim ¹²³	Korea	Korea National Health Insurance Corporation	2000–2005	422194 Women	Colorectal cancer mortality	Nondrinkers 1.0 to 14.9 g/day 15.0 to 29.9 g/day	1 0.99 (0.62 to 1.59) 2.51 (1.31 to 4.82)
				919199 Men		Nondrinkers 1.0 to 14.9 g/day 15.0 to 29.9 g/day	1 1.14 (0.90 to 1.45) 1.06 (0.80 to 1.40)
2011 Breslow ¹²⁹	US	National Health Interview Survey	1988–2006	323354 Women/Men	Colorectal cancer mortality	Never drinker Light (≤ 3 drinks/wk) Moderate (> 3 – 7 drinks/wk for Women, > 3 – 14 drinks/wk for Men) Never drinker	1 0.86 (0.67 to 1.10) 1.04 (0.78 to 1.39) 1
				184764			

				Women		Light (≤3 drinks/wk)	0.74 (0.53 to 1.03)
						Moderate (>3–7 drinks/wk for Women, >3–14 drinks/wk for Men)	0.99 (0.59 to 1.68)
				138590 Men		Never drinker	1
						Light (≤3 drinks/wk)	1.05 (0.66 to 1.67)
						Moderate (>3–7 drinks/wk for Women, >3–14 drinks/wk for Men)	1.22 (0.78 to 1.91)
2013 Shen ¹²⁶	HongKong	18 Elderly Health Centers of the Hong Kong Government Department of Health	1998–2012	66820 Women/Men (22680 Men, 44140 Women)	Colorectal cancer mortality	Never	1
						Social (<1/wk)	0.96 (0.78 to 1.18)
						Wkly social (<10g/day)	1.24 (0.75 to 2.06)
						Moderate(≤30g/day for Men, ≤20g/day for Women)	0.79 (0.54 to 1.16)
				44140 Women		Never	1
						Social (<1/wk)	0.98 (0.71 to 1.35)
						Wkly social (<10g/day)	0.61 (0.15 to 2.47)
						Moderate(≤30g/day for Men, ≤20g/day for Women)	0.46 (0.11 to 1.83)
				22680 Men		Never	1
						Social (<1/wk)	0.98 (0.76 to 1.28)
						Wkly social (<10g/day)	1.51 (0.87 to 2.61)
						Moderate(≤30g/day for Men, ≤20g/day for Women)	0.88 (0.59 to 1.33)
2000 Gaziano ¹³⁰	US	Physicians' Health Study	1982–1990	89299 Men	Colon cancer mortality	Never	1.0
						1–3 drinks/mo	1.28 (0.61 to 2.69)
						1 drinks/wk	0.88 (0.40 to 1.93)
						2–4 drinks/wk	1.08 (0.55 to 2.11)

						5–6 drinks/wk	0.84 (0.36 to 1.97)
						1 drink/day	1.21 (0.66 to 2.20)
Liver cancer mortality							
2010 Kim ¹²³	Korea	Korea National Health Insurance Corporation	2000–2005	422194 Women	Liver cancer mortality	Nondrinkers	1
						1.0 to 14.9 g/day	0.74 (0.44 to 1.22)
						15.0 to 29.9 g/day	1.80 (0.90 to 3.57)
				919199 Men		Nondrinkers	1
						1.0 to 14.9 g/day	0.92 (0.80 to 1.05)
						15.0 to 29.9 g/day	0.95 (0.82 to 1.11)
2013 Shen ¹²⁶	HongKong	18 Elderly Health Centers of the Hong Kong Government Department of Health	1998–2012	66820 Women/Men(22680 Men, 44140 Women)	Liver cancer mortality	Never	1
						Social (<1/wk)	0.81 (0.62 to 1.06)
						Wkly social (<10g/day)	1.15 (0.63 to 2.12)
						Moderate(≤30g/day for Men, ≤20g/day for Women)	1.16 (0.79 to 1.71)
				44140 Women		Never	1
						Social (<1/wk)	0.70 (0.42 to 1.17)
						Wkly social (<10g/day)	1.11 (0.28 to 4.54)
						Moderate(≤30g/day for Men, ≤20g/day for Women)	0.83 (0.20 to 3.34)
				22680 Men		Never	1
						Social (<1/wk)	0.86 (0.62 to 1.19)
						Wkly social (<10g/day)	1.17 (0.59 to 2.32)
						Moderate(≤30g/day for Men, ≤20g/day for Women)	1.24 (0.82 to 1.88)
Pancreatic cancer mortality							
2000 Gaziano ¹³⁰	US	Physicians' Health Study	1982–1990	89299 Men	Pancreatic	Never	1

					cancer mortality	1–3 drinks/mo	0.89 (0.40 to 1.97)
						1 drinks/wk	0.50 (0.20 to 1.25)
						2–4 drinks/wk	0.52 (0.23 to 1.15)
						5–6 drinks/wk	0.72 (0.30 to 1.72)
						1 drink/day	0.79 (0.42 to 1.49)
2010 Kim ¹²³	Korea	Korea National Health Insurance Corporation	2000–2005	422194 Women	Pancreatic cancer mortality	Nondrinkers	1
						1.0 to 14.9 g/day	0.66 (0.35 to 1.23)
						15.0 to 29.9 g/day	0.50 (0.12 to 2.05)
				919199 Men		Nondrinkers	1
						1.0 to 14.9 g/day	0.81 (0.61 to 1.06)
						15.0 to 29.9 g/day	0.98 (0.73 to 1.31)
2011 Gapstur ¹³¹	US	Cancer Prevention Study II	1982–2006	1030467 Women/Men	Pancreatic cancer mortality	Nondrinkers	1
						1 drink/day	1.03 (0.91 to 1.16)
						2 drinks/day	1.04 (0.92 to 1.18)
2013 Shen ¹²⁶	HongKong	18 Elderly Health Centers of the Hong Kong Government Department of Health	1998–2012	66820 Women/Men (22680 Men, 44140 Women)	Pancreatic cancer mortality	Never	1
						Social (<1/wk)	1.15 (0.77 to 1.71)
						Wkly social (<10g/day)	1.49 (0.54 to 4.08)
						Moderate(≤30g/day for Men, ≤20g/day for Women)	0.54 (0.20 to 1.48)
				44140 Women		Never	1
						Social (<1/wk)	0.75 (0.38 to 1.48)
						Wkly social (<10g/day)	NA
						Moderate(≤30g/day for Men, ≤20g/day for Women)	NA
				22680 Men		Never	1
						Social (<1/wk)	1.59 (0.93 to 2.73)

						Wkly social (<10g/day)	2.58 (0.90 to 7.39)
						Moderate(≤30g/day for Men, ≤20g/day for Women)	0.74 (0.26 to 2.09)
GB cancer mortality							
2008 Yagyu ¹³²	Japan	Japan Collaborative Cohort Study	1988–2003	113496 Women/Men	GB cancer mortality	None	1
				Women		0 to 5.9 g/day	1.49 (0.59 to 3.74)
						6.0 to 11.9 g/day	1.14 (0.28 to 4.70)
						12.0 to 23.9 g/day	no mortality
				Men		None	1
						0 to 23.9 g/day	0.90 (0.25 to 3.20)
						24.0 to 47.9 g/day	1.60 (0.58 to 4.44)
						48.0 to 71.9 g/day	2.13 (0.74 to 6.15)
Lung cancer mortality							
1997 Camargo ¹²⁷	US	Physicians' Health Study	1981–1993	22071 Men	Lung cancer mortality	< 1drink/wk	1
						1 to 6 drinks/wk	1.06 (0.56 to 2.00)
2000 Gaziano ¹³⁰	US	Physicians' Health Study	1982–1990	89299 Men	Lung cancer mortality	Never	1.0
						1–3 drinks/mo	0.50 (0.25– 1.01)
						1 drinks/wk	0.63 (0.34 to 1.16)
						2–4 drinks/wk	0.97 (0.60 to 1.57)
						5–6 drinks/wk	0.85 (0.48 to 1.52)
						1 drink/day	0.89 (0.58 to 1.36)
2009 Thun ¹³³	US	Cancer Prevention Study II	1982–2006	150247 Women	Lung cancer mortality	<1 drink/d	1.14 (0.95 to 1.35)
						1 drink/day	1.04 (0.76 to 1.43)
				72969 Men		Nondrinkers	1
						<1 drink/d	0.99 (0.78 to 1.26)
						1 drink/day	1.04 (0.71 to 1.53)

						2–3 drinks/d	0.99 (0.75 to 1.31)
2010 Kim ¹²³	Korea	Korea National Health Insurance Corporation	2000–2005	422194 Women	Lung cancer mortality	Nondrinkers	1
						1.0 to 14.9 g/day	1.29 (0.91 to 1.83)
						15.0 to 29.9 g/day	0.94 (0.45 to 1.94)
				919199 Men		Nondrinkers	1
						1.0 to 14.9 g/day	0.75 (0.66 to 0.85)
						15.0 to 29.9 g/day	0.78 (0.68 to 0.90)
2011 Breslow ¹²⁹	US	National Health Interview Survey	1988–2006	323354 Women/Men	Lung cancer mortality	Never drinker	1
						Light (≤3 drinks/wk)	0.79 (0.67– 0.92)
						Moderate (>3–7 drinks/wk for Women, >3–14 drinks/wk for Men)	0.85 (0.72 to 1.01)
				184764 Women		Never drinker	1
						Light (≤3 drinks/wk)	0.70 (0.56 to 0.89)
						Moderate (>3–7 drinks/wk for Women, >3–14 drinks/wk for Men)	0.83 (0.61 to 1.12)
				138590 Men		Never drinker	1
						Light (≤3 drinks/wk)	0.81 (0.64 to 1.02)
						Moderate (>3–7 drinks/wk for Women, >3–14 drinks/wk for Men)	0.85 (0.67 to 1.07)
2013 Shen ¹²⁶	HongKong	18 Elderly Health Centers of the Hong Kong Government Department of Health	1998–2012	66820 Women/Men(22680 Men, 44140 Women)	Lung cancer mortality	Never	1
						Social (<1/wk)	0.85 (0.74 to 0.98)
						Wkly social (<10g/day)	0.83 (0.57 to 1.21)
						Moderate(≤30g/day for Men, ≤20g/day for Women)	0.93 (0.75 to 1.16)
				44140 Women		Never	1
						Social (<1/wk)	0.91 (0.73 to 1.14)

22680 Men	Wkly social (<10g/day)	NA
	Moderate(≤30g/day for Men, ≤20g/day for Women)	0.98 (0.55 to 1.75)
	Never	1
	Social (<1/wk)	0.82 (0.68 to 0.98)
	Wkly social (<10g/day)	0.69 (0.43 to 1.10)
	Moderate(≤30g/day for Men, ≤20g/day for Women)	0.92 (0.73 to 1.16)

Breast cancer mortality							
1988 Garfinkel ¹²²	US	American Cancer Society's study	1959–1972	581321 Women	Breast cancer mortality	None	1
						occasional	0.96 (0.82 to 1.13)
						1 drink/day	1.18 (1.03 to 1.36)
						2 drinks/day	1.06 (0.86 to 1.30)
1995 Fuchs ¹³⁴	US	Nurses' Health Study	1980–1992	85709 Women	Breast cancer mortality	0	1
						0.1 to 1.4 g/day	0.67 (0.45 to 1.01)
						1.5 to 4.9 g/day	0.85 (0.61 to 1.16)
						5.0 to 14.9 g/day	0.96 (0.71 to 1.32)
1997 Thun ¹²⁸	US	Cancer Prevention Study II	1982–1991	230552 Women	Breast cancer mortality	0	1
						less than daily	1.1 (0.9 to 1.3)
						1 drink/day	1.2 (1.0 to 1.6)
2000 Jain ¹³⁵	Canada	National Breast Screening Study (NBSS)	1980–1993	58926 Women	Breast cancer mortality	0	1
						>0 to ≤10 g/day	1.01 (0.99 to 1.03)
						>10 to ≤20 g/day	1.04 (1.01 to 1.07)
2010 Kim ¹²³	Korea	Korea National Health Insurance Corporation	2000–2005	422194 Women	Breast cancer mortality	Nondrinkers	1
						1.0 to 14.9 g/day	0.82 (0.42 to 1.62)
						15.0 to 29.9 g/day	1.33 (0.46 to 3.86)
2011 Breslow ¹²⁹	US	National Health Interview	1988–2006	184764	Breast cancer	Never drinker	1

Survey				Women	mortality	Light (≤3 drinks/wk)	0.75 (0.57 to 0.98)
						Moderate (>3–7 drinks/wk for Women, >3–14 drinks/wk for Men)	1.02 (0.66 to 1.57)
2013 Shen ¹²⁶	HongKong	18 Elderly Health Centers of the Hong Kong Government Department of Health	1998–2012	44140 Women	Breast cancer mortality	Never	1
						Social (<1/wk)	0.87 (0.45 to 1.67)
						Wkly social (<10g/day)	NA
						Moderate(≤30g/day for Men, ≤20g/day for Women)	NA
Uterine cancer mortality							
2010 Kim ¹²³	Korea	Korea National Health Insurance Corporation	2000–2005	422194 Women	Uterine cancer mortality	Nondrinkers	1
						1.0 to 14.9 g/day	1.09 (0.50 to 2.35)
						15.0 to 29.9 g/day	1.10 (0.25 to 4.79)
Prostate cancer mortality							
1997 Camargo ¹²⁷	US	Physicians' Health Study	1981–1993	22071 Men	Prostate cancer mortality	0	1
						1 to 6 drinks/wk	0.88 (0.49 to 1.60)
						1 drink/day	0.6 (0.4 to 0.8)
2000 Gaziano ¹³⁰	US	Physicians' Health Study	1982–1990	89299 Men	Prostate cancer mortality	Never	1
						1–3 drinks/mo	0.56 (0.21 to 1.50)
						1 drinks/wk	0.09 (0.01 to 0.71)
						2–4 drinks/wk	0.86 (0.42 to 1.78)
						5–6 drinks/wk	0.69 (0.27 to 1.76)
						1 drink/day	1.01 (0.55 to 1.85)
2010 Kim ¹²³	Korea	Korea National Health Insurance Corporation	2000–2005	919199 Men	Prostate cancer mortality	Nondrinkers	1
						1.0 to 14.9 g/day	1.32 (0.59 to 3.00)
						15.0 to 29.9 g/day	1.75 (0.72 to 4.22)
2011 Breslow ¹²⁹	US	National Health Interview Survey	1988–2006	138590 Men	Prostate cancer mortality	Never drinker	1
						Light (≤3 drinks/wk)	0.93 (0.66 to 1.30)

						Moderate (>3–7 drinks/wk for Women, >3–14 drinks/wk for Men)	1.22 (0.86 to 1.72)
2013 Shen ¹²⁶	HongKong	18 Elderly Health Centers of the Hong Kong Government Department of Health	1998–2012	22680 Men	Prostate cancer mortality	Never	1
						Social (<1/wk)	0.92 (0.61 to 1.39)
						Wkly social (<10g/day)	0.83 (0.26 to 2.64)
						Moderate(≤30g/day for Men, ≤20g/day for Women)	0.87 (0.46 to 1.63)
Kidney cancer mortality							
2010 Kim ¹²³	Korea	Korea National Health Insurance Corporation	2000–2005	919199 Men	Kidney cancer mortality	Nondrinkers	1
						1.0 to 14.9 g/day	0.63 (0.35 to 1.12)
						15.0 to 29.9 g/day	0.46 (0.23 to 0.93)
Hematologic malignancy mortality							
2000 Gaziano ¹³⁰	US	Physicians' Health Study	1982–1990	89299 Men	Hematologic malignancy mortality	Never	1.0
						1–3 drinks/mo	1.09 (0.59 to 2.04)
						1 drinks/wk	1.08 (0.60 to 1.96)
						2–4 drinks/wk	0.87 (0.49 to 1.53)
						5–6 drinks/wk	0.70 (0.33 to 1.45)
						1 drink/day	0.67 (0.38 to 1.15)
2010 Kim ¹²³	Korea	Korea National Health Insurance Corporation	2000–2005	919199 Men	Hematologic malignancy (leukemia) mortality	Nondrinkers	1
						1.0 to 14.9 g/day	0.76 (0.48 to 1.20)
						15.0 to 29.9 g/day	1.00 (0.63 to 1.6)
2013 Shen ¹²⁶	HongKong	18 Elderly Health Centers of the Hong Kong Government Department of Health	1998–2012	66820 Women/Men (22680 Men, 44140 Women)	Hematologic malignancy (leukemia) mortality	Never	1
						Social (<1/wk)	1.14 (0.68 to 1.94)
						Wkly social (<10g/day)	2.45 (0.88 to 6.82)
						Moderate (≤30g/day for Men, ≤20g/day for Women)	1.70 (0.76 to 3.84)

				44140 Women		Never	1
						Social (<1/wk)	0.95 (0.43 to 2.07)
						Wkly social (<10g/day)	3.26 (0.79 to 13.48)
						Moderate (≤30g/day for Men, ≤20g/day for Women)	NA
				22680 Men		Never	1
						Social (<1/wk)	1.51 (0.70 to 3.26)
						Wkly social (<10g/day)	2.25 (0.51 to 9.91)
						Moderate (≤30g/day for Men, ≤20g/day for Women)	2.45 (1.00 to 6.00)
Laryngeal cancer mortality							
2010 Kim ¹²³	Korea	Korea National Health Insurance Corporation	2000–2005	919199 Men	Laryngeal cancer mortality	Nondrinkers	1
						1.0 to 14.9 g/day	1.31 (0.60 to 2.85)
						15.0 to 29.9 g/day	0.87 (0.32 to 2.35)

S3 Table. Methodological quality of studies in the final analysis based on the Newcastle-Ottawa Scale - incidence

Study	Country	Cohort	Follow-up period	S1	S2	S3	S4	C	O1	O2	O3	Total score
1988 Klatsky ³⁴	US	members of Kaiser Permanente Medical Care Program in Northern California	1978-1984	1	1	0	0	2	1	1	0	6
1989 Schaatzkin ⁵¹	US	Framingham Heart Study	1948-1980	1	1	1	1	2	1	1	1	9
1990 Stemmermann ³⁵	US	American men of Japanese ancestry residing in Hawaiian island (Oahu)	1965-1989	1	1	0	0	2	1	1	0	6
1991 Simon ⁵²	US	Tecumseh Community Health Study (TCHS)	1959-1960	1	1	1	0	2	1	1	0	7
1992 Gapstur ⁵³	US	Iowa Women's Health Study	1986-1989	1	1	0	1	2	1	0	0	6
1993 Chyou ¹⁰⁸	Japan	American men of Japanese ancestry residing in Hawaiian island	1965-1991	1	1	1	1	2	1	1	1	9
1993 Gapstur ⁸¹	US	Iowa Women's Health Study	1986-1990	1	1	0	1	2	1	0	0	6
1994 Goldbohm ³⁶	Netherlands	from 204 municipal population registries throughout the country	1986-1989	1	1	0	1	2	1	0	0	6
1995 Giovannucci ³⁷	US	male health professionals	1986-1992	0	1	0	1	2	1	1	1	7
1995 Nomura ¹¹	Japan	American men of Japanese ancestry residing in Hawaiian island	1965-1990	1	1	1	1	2	1	1	1	9
1995 van den Brandt ⁵⁴	Netherlands	Netherlands Cohort Study	1986-1989	1	1	0	1	2	1	0	0	6
1998 Galanis ¹²	US	Japanese residents of Hawaii	1975-1994	1	1	1	1	2	1	1	0	8
1999 Breslow ⁹⁰	US	National Health and Nutrition Examination Survey (NHANES I)	1971-1992	1	1	1	1	2	1	1	0	8

1999 Chiu ¹¹⁴	US	Iowa Women's Health Study	1987-1992	1	1	0	1	2	1	1	0	7
1999 Garland ⁵⁵	US	Nurses' Health Study II	1989-1995	0	1	0	1	2	1	1	0	6
1999 Parker ⁹¹	US	NCI's SEER program -> IOWA Cancer Registry	1980-1995	1	1	0	0	2	1	1	1	7
1999 Prescott ⁴⁶	Denmark	Copenhagen City Heart Study	1964-1992	1	1	0	0	2	1	1	1	7
1999 Schuurman ⁹²	Netherlands	Netherlands Cohort Study	1986-1992	1	1	0	1	2	1	1	1	8
1999 Terry ⁸²	Sweden	Swedish Twin Registry	1967-1992	0	1	1	1	2	1	1	0	7
1999 Zhang ⁵⁶	US	Framingham Original Cohort & Offspring Cohort	1948-1993, 1971-1993	1	1	0	0	2	1	1	0	6
2000 Ellison ⁹³	Canada	Nutrition Canada Survey (NCS)	1970-1993	1	1	1	2	2	1	0	0	8
2000 Rohan ⁵⁷	Canada	Canadian National Breast Screening Study (NBSS)	1980-1993	1	1	0	0	2	1	1	0	6
2001 Feigelson ⁵⁸	US	American Cancer society Cancer Prevention Study II Nutrition Cohort (CPS-II Nutrition Cohort)	1982-1996	1	1	0	1	2	1	1	0	7
2001 Michaud ⁴²	US	Nurses' Health Study	1980-1996	0	1	0	1	2	1	1	1	7
2001 Sesso ⁹⁴	US	Harvard alumni	1988-1993	0	1	0	1	2	0	1	1	6
2001 Stolzenberg-Solomon ⁴³	US	Alpha-Tocopherol Beta-Carotene Cancer Prevention Study cohort	1985-1997	0	1	0	1	2	1	1	0	6
2001 Zeegers ¹⁰⁹	Netherlands	Netherlands Cohort Study	1986-1992	1	1	0	1	2	1	1	0	7
2002 Albertsen ⁹⁵	Denmark	Copenhagen Centre for Prospective Population Studies	1976-1994	1	1	0	0	2	1	1	1	7
2002 Chen ⁵⁹	US	Nurses' Health Study	1980-1994	0	1	0	1	2	1	1	0	6
2002 Djousse ⁴⁷	US	Framingham Study cohort, offspring cohort	1948, 1971	1	1	0	0	2	1	1	0	6

2002 Flood ²⁰	US	Breast Cancer Detection Demonstration Project (BCDDP)	1987-1995	1	1	0	1	2	1	1	1	8
2002 Horn-Ross ⁶⁰	US	California Teachers Study cohort	1995-1998	0	1	0	1	2	1	0	1	6
2002 Isaksson ⁴⁴	Sweden	Swedish Twin Registry	1969-1997	0	1	0	0	2	1	1	0	5
2003 Feigelson ⁶¹	US	American Cancer society Cancer Prevention Study II Nutrition Cohort (CPS-II Nutrition Cohort)	1992-1998	1	1	0	1	2	1	1	0	7
2003 Freedman ¹²⁰	US	US Radiologic Technologists (USRT) Study	1983-1998	0	1	0	0	2	1	1	0	5
2003 Otani ²¹	Japan	Japan Public Health Center-based prospective study(cohort I)	1990-1999	1	1	0	1	2	1	1	1	8
2003 Pederson ³⁸	Denmark	Copenhagen Centre for Prospective Population Studies	1970-1999	1	1	0	0	2	1	1	1	7
2004 Dumeaux ⁶²	Norway	Norwegian Women and Cancer Study	1991-2001	1	1	0	1	2	1	1	0	7
2004 Horn-Ross ⁶³	US	California Teachers Study cohort	1995-2001	0	1	0	1	2	1	1	0	6
2004 Platz ⁹⁶	US	Health Professionals Follow-up Study	1986-1998	0	1	0	1	2	1	1	1	7
2004 Sanjoaquin ²²	UK	Oxford Vegetarian Study	1980-1999	0	1	0	1	2	1	1	0	6
2004 Sellers ⁶⁴	US	Iowa Women's Health Study	1986-1999	1	1	0	1	2	1	1	0	7
2004 Su ³⁹	US	National Health and Nutrition Examination Survey (NHANES I)	1982-1993	1	1	0	1	2	1	1	0	7
2004 Wei ⁴⁰	US	Nurses' Health Study, Health Professionals Follow-up Study	NHS 1980-2000, HPFS 1986-2000	0	1	0	1	2	1	1	0	6
2005 Barstad ¹³	Denmark	Copenhagen Centre for Prospective Population Studies	1964-1992	1	1	0	0	2	1	1	1	7

2005 Chen ²³	China	population of Jiashan County	1989-2001	1	1	0	1	2	1	1	0	7
2005 Freudenheim ⁴⁸	US	pooled cohort(ATBC, HPFU, NLCS, NYSC)	Various	1	1	0	0	2	1	1	0	6
2005 Mahabir ¹⁰³	US	Alpha-Tocopherol BetaCarotene (ATBC) Cancer Prevention Study	1985-1999	0	1	0	1	2	1	1	0	6
2005 Navarro Silvera ¹¹⁰	Canada	Canadian National Breast Screening Study (NBSS)	1982-2000	1	1	0	0	2	1	1	0	6
2005 Suzuki ⁶⁵	Sweden	Swedish Mammography Cohort	1987-2004	1	1	0	1	2	1	1	0	7
2006 Mellekjar ⁶⁶	Denmark	Danish Prospective Cohort Study	1993-2002	1	1	0	1	2	1	1	0	7
2006 Stolzenberg- Solomon ⁶⁷	US	Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial	1993-2001	1	1	0	1	2	1	1	0	7
2006 Velicer ⁹⁸	US	VITAL Study	2000-2004	1	1	0	1	2	1	0	0	6
2006 Weinstern ⁹⁷	US	Alpha-Tocopherol Beta-Carotene Cancer Prevention Study cohort	1985-2002	0	1	0	1	2	1	1	0	6
2007 Chang ⁸⁸	US	California Teachers Study cohort	1995-2003	0	1	0	1	2	1	1	0	6
2007 Freedman ¹	US	NIH-AARP Diet and Health Study	1995-2000	1	1	0	1	2	1	1	0	7
2007 Friborg ⁵	Singapore	Singapore Chinese Health Study	1993-2005	1	1	1	1	2	1	1	0	8
2007 Larsson ¹⁴	Sweden	Swedish Mammography Cohort	1987-2005	1	1	0	0	2	1	1	0	6
2007 Lim ¹¹⁵	US	NIH-AARP Diet and Health Study	1995-2000	1	1	0	1	2	1	0	1	7
2007 Loerbroks ⁸³	Netherlands	Netherlands Cohort Study	1986-1997	1	1	0	1	2	1	1	1	8
2007 Setiawan ¹⁰⁴	US	Hawaii-Los Angeles Multiethnic Cohort	1993-2002	1	1	0	1	2	1	1	1	8
2007 Sung ¹⁵	Korea	National Health Insurance Corporation Study	1996-2002	1	1	0	0	2	1	1	0	6

2007 Sutcliffe ⁹⁹	US	Health Professionals Follow-up Study (HPFS)	1986-2002	0	1	0	1	2	1	1	1	7
2007 Tjonneland ⁶⁸	Europe	European Prospective Investigation into Cancer and Nutrition (EPIC)	Various	1	1	0	0	2	1	1	0	6
2007 Tsong ²⁴	Singapore	Singapore Chinese Health Study	1993-1998	1	1	1	1	2	1	1	0	8
2007 Zhang ⁶⁹	US	Women's Health Study (US female health professionals)	1992-2004	0	1	0	1	2	1	1	1	7
2008 Bongaerts ²⁵	Netherlands	Netherlands Cohort Study	1986-1999	1	1	0	1	2	1	1	0	7
2008 Fan ⁸	China	Shanghai Cohort Study	1986-2006	1	1	1	1	2	1	1	1	9
2008 Kabat ²⁶	Canada	Canadian National Breast Screening Study	1980-2000	1	1	0	1	2	1	1	0	7
2008 Schouten ¹⁰⁵	Netherlands	NLCS on Diet and Cancer	1986-1997	1	1	0	1	2	1	1	1	8
2008 Setiawan ⁸⁴	US	Multiethnic Cohort Study in California and Hawaii	1993-2002	1	1	0	1	2	1	1	0	7
2008 Thygesen ²⁷	US	Health Professional Follow-up Study	1986-2002	1	1	0	0	2	1	1	0	6
2008 Toriola ²⁸	Finland	Kuopio Ischemic Heart Study (KIHD)	1984-2005	1	1	0	1	2	1	1	1	8
2008 Tworoger ⁸⁹	US	Nurses' Health Study (NHS)	1976-2004	0	1	0	1	2	1	1	1	7
2009 Allen ²	UK	Million Women Study	1996-2001	1	1	0	0	2	1	1	0	6
2009 Friberg ⁸⁵	Sweden	Swedish Mammography Cohort	1987-1997	1	1	0	0	2	1	1	1	7
2009 Gong ¹⁰⁰	US	Prostate Cancer Prevention Trial	1996-1993	0	1	0	1	2	1	1	0	6
2009 Heinen ⁴⁵	Netherlands	Netherlands Cohort Study	1986-1999	1	1	0	1	2	1	1	0	7
2009 Klatsky ¹¹⁶	US	members of comprehensive pre-paid health care programme in SF Bay area	1978-2006	1	1	0	1	2	1	1	0	7
2009 Lew ⁷⁰	US	NIH-AARP Diet and Health Study	1995-2003	1	1	0	1	2	1	1	0	7
2009 Meinhold ¹¹¹	US	NIH-AARP Diet and Health Study	1995-1996	1	1	0	1	2	1	1	0	7

2009 Park ²⁹	UK	UK Norfolk arm of EPIC study	1995-2003	1	1	0	1	2	1	1	0	7
2010 Chang ¹¹⁷	US	California Teachers Study	1995-2007	0	1	0	1	2	1	1	0	6
2010 Chao ¹⁰¹	US	California Men's Health Study (CMHS)	2002-2007	1	1	0	1	2	1	1	0	7
2010 Li ⁷¹	US	Women's Health Initiative - observational study (WHI-OS)	1993-2005	1	1	0	1	2	1	1	0	7
2010 Meinhold ¹¹²	US	US Radiologic Technologists Study	1983-2006	1	1	0	1	2	1	1	0	7
2010 Moy ¹⁶	China	Shanghai Cohort Study	1986-2005	1	1	1	1	2	1	1	1	9
2010 Shanmugham ³	US	Nurses' Health Study	1980-2006	0	1	0	1	2	1	1	1	7
2010 Steevens ⁹	Netherland	Netherlands Cohort Study	1986-2002	1	1	0	1	2	1	1	1	8
2010 Troy ¹¹⁸	US	PLCO Cancer Screening Trial	1993-2006	1	1	0	1	2	1	1	0	7
2010 Watters ¹⁰²	US	NIH-AARP Diet and Health Study	1995-2005	1	1	0	1	2	1	1	0	7
2011 Chao ⁴⁹	US	VITAL Study	2000-2007	1	1	0	1	2	1	1	0	7
2011 Chen ⁷²	US	Nurses' Health Study	1980-2008	0	1	0	1	2	1	1	1	7
2011 Kawai ⁷³	Japan	The Miyagi Cohort Study	1990-2003	1	1	0	1	2	1	1	1	8
2011 Razzak ³⁰	US	Iowa Women's Health Study	1986-2004	1	1	0	1	2	1	1	0	7
2011 Yang ⁸⁶	US	NIH-AARP Diet and Health study	1995-2006	1	1	0	1	2	1	1	0	7
2012 Cho ⁴¹	US	Health Professional Follow-up Study, Nurses' Health Study	1980-2006	0	1	0	1	2	1	1	1	7
2012 Everatt ¹⁷	Lithuania	KRIS, MIHDP	1972-2008	1	1	1	1	2	1	1	0	8
2012 Gapstur ¹¹⁹	US	Cancer Prevention Study II Nutrition cohort	1992-2007	1	1	0	1	2	1	1	0	7
2012 Kabat ¹¹³	US	Women's Health Initiative	1993-2002	1	1	0	1	2	1	1	1	8
2012 Macleod ¹⁰⁶	US	VITAL study	2000-2009	1	1	0	1	2	1	1	0	7

2013 Everatt ³¹	Lithuania	Kaunas Rotterdam Intervention Study (KRIS), Multifactorial Ischemic Heart Disease Prevention Study (MIHDPS)	1978-2008	1	1	0	1	2	1	1	0	7
2013 Hashibe ⁶	US	Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Cohort(PLCO)	1992-2001	1	1	0	1	2	1	1	0	7
2013 Liu ⁷⁴	US	Nurses' Health Study II	1989-2009	0	1	0	1	2	1	1	0	6
2014 Falk ⁷⁵	US	Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Cohort	1993-2009	1	1	0	1	2	1	1	0	7
2014 Je ⁸⁷	US	Nurses' Health Study	1980-2010	0	1	0	1	2	1	1	0	6
2014 Kubo ¹²¹	US	Women's Health Initiative - observational study (WHI-OS)	1993-2010	1	1	0	1	2	1	1	0	7
2014 Maasland ⁷	Netherlands	Netherlands Cohort Study	1986-2003	1	1	0	1	2	1	1	1	8
2014 Nishihara ³²	US	Nurses' Health Study, Health Professionals Follow-up Study	1976-2008	0	1	0	1	2	1	1	0	6
2014 Park ⁷⁶	US	Multiethnic Cohort in California and Hawaii	1993-2007	1	1	0	1	2	1	1	0	7
2014 Yates ¹⁰	UK	EPIC-Norfolk Study	1993-2008	1	1	0	1	2	1	1	1	8
2015 Chhim ⁷⁷	France	SU.VI.MAX	1994-2007	0	1	0	1	2	1	1	0	6
2015 Cho ³³	Korea	Korean Multi-center Cancer Cohort	1993-2005	1	1	1	1	2	1	1	0	8
2015 Eom ¹⁸	Korea	Korean National Health Insurance Corporation data	1998-2007	1	1	0	1	2	1	1	0	7
2015 Fagherazzi ⁷⁸	France	French E3N-EPIC cohort	1993-2008	1	1	0	1	2	1	1	0	7
2015 Hippisley-Cox ⁴	UK	primary care patients from open cohort study using Qresearch database (EMIS computer system)	1998-2013	1	1	1	1	2	1	1	0	8

2015 Karami ¹⁰⁷	US	Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO)	1993-2001	1	1	0	1	2	1	1	0	7
2015 Klatsky ¹⁹	US	multiethnic Northern California population (Kaiser Permanente)	1978-2012	1	1	0	0	2	1	1	0	6
2015 Shin ⁷⁹	Sweden	Swedish Women's Lifestyle and Health study	1991-2009	1	1	0	1	2	1	1	0	7
2016 Nitta ⁸⁰	Japan	Japan Collaborative Cohort Study (JACC)	1988-2009	1	1	0	1	2	1	1	0	7
2016 Troche ⁵⁰	US	NIH-AARP Diet and Health Study	1995-2006	1	1	0	1	2	1	1	0	7

S, selection; C, comparability; O, Outcome. Refer to the following link for more information: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

S4Table. Methodological quality of studies in the final analysis based on the Newcastle-Ottawa Scale – mortality

Study	Country	Cohort	Follow-up period	S1	S2	S3	S4	C	O1	O2	O3	Total
1988 Garfinkel ¹²²	US	American Cancer Society's study	1959-1972	1	1	0	0	2	1	1	1	7
1990 Boffetta ¹²⁴	US	American Cancer Society	1959-1972	1	1	0	0	2	1	1	1	7
1995 Fuchs ¹³⁴	US	Nurses' Health Study	1980-1992	0	1	0	1	2	1	1	0	6
1997 Camargo ¹²⁷	US	Physicians' Health Study	1981-1993	0	1	0	1	2	1	1	0	6
1997 Thun ¹²⁸	US	Cancer Prevention Study II	1982-1991	1	1	0	1	2	1	1	1	8
2000 Gaziano ¹³⁰	US	Physicians' Health Study	1982-1990	0	1	0	1	2	1	1	0	6
2000 Jain ¹³⁵	Canada	National Breast Screening Study (NBSS)	1980-1993	1	1	0	1	2	1	1	0	7
2005 Sakata ¹²⁵	Japan	JACC Study	1988-1994	1	1	0	1	2	1	1	0	7
2008 Yagyu ¹³²	Japan	Japan Collaborative Cohort Study	1988-2003	1	1	0	1	2	1	1	0	7
2009 Thun ¹³³	US	Cancer Prevention Study II	1982-2006	1	1	0	1	2	1	1	0	7
2010 Kim ¹²³	Korea	Korea National Health Insurance Corporation	2000-2005	1	1	0	1	2	1	1	0	7

2011 Breslow ¹²⁹	US	National Health Interview Survey	1988-2006	1	1	1	0	2	1	1	0	7
2011 Gapstur ¹³¹	US	Cancer Prevention Study II	1982-2006	1	1	0	1	2	1	1	1	8
2013 Shen ¹²⁶	HongKong	18 Elderly Health Centres of the Hong Kong Government Department of Health	1998-2012	1	1	1	0	2	1	1	0	7

S, selection; C, comparability; O, Outcome. Refer to the following link for more information: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

Supplementary References

1. Freedman ND, Schatzkin A, Leitzmann MF, Hollenbeck AR, Abnet CC. Alcohol and head and neck cancer risk in a prospective study. *Br J Cancer*. 2007;96:1469-74.
2. Allen NE, Beral V, Casabonne D, Kan SW, Reeves GK, Brown A, et al. Moderate alcohol intake and cancer incidence in women. *J Natl Cancer Inst*. 2009;101:296-305.
3. Shanmugham JR, Zavras AI, Rosner BA, Giovannucci EL. Alcohol-folate interactions in the risk of oral cancer in women: a prospective cohort study. *Cancer Epidemiol Biomarkers Prev*. 2010;19:2516-24.
4. Hippisley-Cox J, Coupland C. Development and validation of risk prediction algorithms to estimate future risk of common cancers in men and women: prospective cohort study. *BMJ Open*. 2015;5:e007825.
5. Friborg JT, Yuan JM, Wang R, Koh WP, Lee HP, Yu MC. A prospective study of tobacco and alcohol use as risk factors for pharyngeal carcinomas in Singapore Chinese. *Cancer*. 2007;109:1183-91.
6. Hashibe M, Hunt J, Wei M, Buys S, Gren L, Lee YC. Tobacco, alcohol, body mass index, physical activity, and the risk of head and neck cancer in the prostate, lung, colorectal, and ovarian (PLCO) cohort. *Head Neck*. 2013;35:914-22.
7. Maasland DH, van den Brandt PA, Kremer B, Goldbohm RA, Schouten LJ. Alcohol consumption, cigarette smoking and the risk of subtypes of head-neck cancer: results from the Netherlands Cohort Study. *BMC Cancer*. 2014;14:187.
8. Fan Y, Yuan JM, Wang R, Gao YT, Yu MC. Alcohol, tobacco, and diet in relation to esophageal cancer: the Shanghai Cohort Study. *Nutr Cancer*. 2008;60:354-63.
9. Steevens J, Schouten LJ, Goldbohm RA, van den Brandt PA. Alcohol consumption, cigarette smoking and risk of subtypes of oesophageal and gastric cancer: a prospective cohort study. *Gut*. 2010;59:39-48.
10. Yates M, Cheong E, Luben R, Igali L, Fitzgerald R, Khaw KT, et al. Body mass index, smoking, and alcohol and risks of Barrett's esophagus and esophageal adenocarcinoma: a UK prospective cohort study. *Dig Dis Sci*. 2014;59:1552-9.
11. Nomura AM, Stemmermann GN, Chyou PH. Gastric cancer among the Japanese in Hawaii. *Jpn J Cancer Res*. 1995;86:916-23.
12. Galanis DJ, Kolonel LN, Lee J, Nomura A. Intakes of selected foods and beverages

- and the incidence of gastric cancer among the Japanese residents of Hawaii: a prospective study. *Int J Epidemiol*. 1998;27:173-80.
13. Barstad B, Sorensen TI, Tjonneland A, Johansen D, Becker U, Andersen IB, et al. Intake of wine, beer and spirits and risk of gastric cancer. *Eur J Cancer Prev*. 2005;14:239-43.
 14. Larsson SC, Giovannucci E, Wolk A. Alcoholic beverage consumption and gastric cancer risk: a prospective population-based study in women. *Int J Cancer*. 2007;120:373-7.
 15. Sung NY, Choi KS, Park EC, Park K, Lee SY, Lee AK, et al. Smoking, alcohol and gastric cancer risk in Korean men: the National Health Insurance Corporation Study. *Br J Cancer*. 2007;97:700-4.
 16. Moy KA, Fan Y, Wang R, Gao YT, Yu MC, Yuan JM. Alcohol and tobacco use in relation to gastric cancer: a prospective study of men in Shanghai, China. *Cancer Epidemiol Biomarkers Prev*. 2010;19:2287-97.
 17. Everatt R, Tamosiunas A, Kuzmickiene I, Virviciute D, Radisauskas R, Reklaitiene R, et al. Alcohol consumption and risk of gastric cancer: a cohort study of men in Kaunas, Lithuania, with up to 30 years follow-up. *BMC Cancer*. 2012;12:475.
 18. Eom BW, Joo J, Kim S, Shin A, Yang HR, Park J, et al. Prediction Model for Gastric Cancer Incidence in Korean Population. *PLoS One*. 2015;10:e0132613.
 19. Klatsky AL, Li Y, Nicole Tran H, Baer D, Udaltsova N, Armstrong MA, et al. Alcohol intake, beverage choice, and cancer: a cohort study in a large kaiser permanente population. *Perm J*. 2015;19:28-34.
 20. Flood A, Caprario L, Chatterjee N, Lacey JV, Jr., Schairer C, Schatzkin A. Folate, methionine, alcohol, and colorectal cancer in a prospective study of women in the United States. *Cancer Causes Control*. 2002;13:551-61.
 21. Otani T, Iwasaki M, Yamamoto S, Sobue T, Hanaoka T, Inoue M, et al. Alcohol consumption, smoking, and subsequent risk of colorectal cancer in middle-aged and elderly Japanese men and women: Japan Public Health Center-based prospective study. *Cancer Epidemiol Biomarkers Prev*. 2003;12:1492-500.
 22. Sanjoaquin MA, Appleby PN, Thorogood M, Mann JI, Key TJ. Nutrition, lifestyle and colorectal cancer incidence: a prospective investigation of 10998 vegetarians and non-vegetarians in the United Kingdom. *Br J Cancer*. 2004;90:118-21.

23. Chen K, Jiang Q, Ma X, Li Q, Yao K, Yu W, et al. Alcohol drinking and colorectal cancer: a population-based prospective cohort study in China. *Eur J Epidemiol.* 2005;20:149-54.
24. Tsong WH, Koh WP, Yuan JM, Wang R, Sun CL, Yu MC. Cigarettes and alcohol in relation to colorectal cancer: the Singapore Chinese Health Study. *Br J Cancer.* 2007;96:821-7.
25. Bongaerts BW, van den Brandt PA, Goldbohm RA, de Goeij AF, Weijenberg MP. Alcohol consumption, type of alcoholic beverage and risk of colorectal cancer at specific subsites. *Int J Cancer.* 2008;123:2411-7.
26. Kabat GC, Miller AB, Jain M, Rohan TE. Dietary intake of selected B vitamins in relation to risk of major cancers in women. *Br J Cancer.* 2008;99:816-21.
27. Thygesen LC, Wu K, Gronbaek M, Fuchs CS, Willett WC, Giovannucci E. Alcohol intake and colorectal cancer: a comparison of approaches for including repeated measures of alcohol consumption. *Epidemiology.* 2008;19:258-64.
28. Toriola AT, Kurl S, Laukanen JA, Mazengo C, Kauhanen J. Alcohol consumption and risk of colorectal cancer: the Findrink study. *Eur J Epidemiol.* 2008;23:395-401.
29. Park JY, Mitrou PN, Dahm CC, Luben RN, Wareham NJ, Khaw KT, et al. Baseline alcohol consumption, type of alcoholic beverage and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition-Norfolk study. *Cancer Epidemiol.* 2009;33:347-54.
30. Razzak AA, Oxentenko AS, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, et al. Alcohol intake and colorectal cancer risk by molecularly defined subtypes in a prospective study of older women. *Cancer Prev Res.* 2011;4:2035-43.
31. Everatt R, Tamosiunas A, Virviciute D, Kuzmickiene I, Reklaitiene R. Consumption of alcohol and risk of cancer among men: a 30 year cohort study in Lithuania. *Eur J Epidemiol.* 2013;28:383-92.
32. Nishihara R, Wang M, Qian ZR, Baba Y, Yamauchi M, Mima K, et al. Alcohol, one-carbon nutrient intake, and risk of colorectal cancer according to tumor methylation level of IGF2 differentially methylated region. *Am J Clin Nutr.* 2014;100:1479-88.
33. Cho S, Shin A, Park SK, Shin HR, Chang SH, Yoo KY. Alcohol Drinking, Cigarette Smoking and Risk of Colorectal Cancer in the Korean Multi-center Cancer Cohort. *J Cancer Prev.* 2015;20:147-52.

34. Klatsky AL, Armstrong MA, Friedman GD, Hiatt RA. The relations of alcoholic beverage use to colon and rectal cancer. *Am J Epidemiol.* 1988;128:1007-15.
35. Stemmermann GN, Nomura AM, Chyou PH, Yoshizawa C. Prospective study of alcohol intake and large bowel cancer. *Dig Dis Sci.* 1990;35:1414-20.
36. Goldbohm RA, Van den Brandt PA, Van 't Veer P, Dorant E, Sturmans F, Hermus RJ. Prospective study on alcohol consumption and the risk of cancer of the colon and rectum in the Netherlands. *Cancer Causes Control.* 1994;5:95-104.
37. Giovannucci E, Rimm EB, Ascherio A, Stampfer MJ, Colditz GA, Willett WC. Alcohol, low-methionine-low-folate diets, and risk of colon cancer in men. *J Natl Cancer Inst.* 1995;87:265-73.
38. Pedersen A, Johansen C, Gronbaek M. Relations between amount and type of alcohol and colon and rectal cancer in a Danish population based cohort study. *Gut.* 2003;52:861-7.
39. Su LJ, Arab L. Alcohol consumption and risk of colon cancer: evidence from the national health and nutrition examination survey I epidemiologic follow-up study. *Nutr Cancer.* 2004;50:111-9.
40. Wei EK, Giovannucci E, Wu K, Rosner B, Fuchs CS, Willett WC, et al. Comparison of risk factors for colon and rectal cancer. *Int J Cancer.* 2004;108:433-42.
41. Cho E, Lee JE, Rimm EB, Fuchs CS, Giovannucci EL. Alcohol consumption and the risk of colon cancer by family history of colorectal cancer. *Am J Clin Nutr.* 2012;95:413-9.
42. Michaud DS, Giovannucci E, Willett WC, Colditz GA, Fuchs CS. Coffee and alcohol consumption and the risk of pancreatic cancer in two prospective United States cohorts. *Cancer Epidemiol Biomarkers Prev.* 2001;10:429-37.
43. Stolzenberg-Solomon RZ, Pietinen P, Barrett MJ, Taylor PR, Virtamo J, Albanes D. Dietary and other methyl-group availability factors and pancreatic cancer risk in a cohort of male smokers. *Am J Epidemiol.* 2001;153:680-7.
44. Isaksson B, Jonsson F, Pedersen NL, Larsson J, Feychting M, Permert J. Lifestyle factors and pancreatic cancer risk: a cohort study from the Swedish Twin Registry. *Int J Cancer.* 2002;98:480-2.
45. Heinen MM, Verhage BA, Ambergen TA, Goldbohm RA, van den Brandt PA. Alcohol consumption and risk of pancreatic cancer in the Netherlands cohort study. *Am J*

- Epidemiol. 2009;169:1233-42.
46. Prescott E, Gronbaek M, Becker U, Sorensen TI. Alcohol intake and the risk of lung cancer: influence of type of alcoholic beverage. *Am J Epidemiol.* 1999;149:463-70.
 47. Djousse L, Dorgan JF, Zhang Y, Schatzkin A, Hood M, D'Agostino RB, et al. Alcohol consumption and risk of lung cancer: the Framingham Study. *J Natl Cancer Inst.* 2002;94:1877-82.
 48. Freudenheim JL, Ritz J, Smith-Warner SA, Albanes D, Bandera EV, van den Brandt PA, et al. Alcohol consumption and risk of lung cancer: a pooled analysis of cohort studies. *Am J Clin Nutr.* 2005;82:657-67.
 49. Chao C, Li Q, Zhang F, White E. Alcohol consumption and risk of lung cancer in the VITamins And Lifestyle Study. *Nutr Cancer.* 2011;63:880-8.
 50. Troche JR, Mayne ST, Freedman ND, Shebl FM, Abnet CC. The Association Between Alcohol Consumption and Lung Carcinoma by Histological Subtype. *Am J Epidemiol.* 2016;183:110-21.
 51. Schatzkin A, Carter CL, Green SB, Kreger BE, Splansky GL, Anderson KM, et al. Is alcohol consumption related to breast cancer? Results from the Framingham Heart Study. *J Natl Cancer Inst.* 1989;81:31-5.
 52. Simon MS, Carman W, Wolfe R, Schottenfeld D. Alcohol consumption and the risk of breast cancer: a report from the Tecumseh Community Health Study. *J Clin Epidemiol.* 1991;44:755-61.
 53. Gapstur SM, Potter JD, Sellers TA, Folsom AR. Increased risk of breast cancer with alcohol consumption in postmenopausal women. *Am J Epidemiol.* 1992;136:1221-31.
 54. van den Brandt PA, Goldbohm RA, van 't Veer P. Alcohol and breast cancer: results from The Netherlands Cohort Study. *Am J Epidemiol.* 1995;141:907-15.
 55. Garland M, Hunter DJ, Colditz GA, Spiegelman DL, Manson JE, Stampfer MJ, et al. Alcohol consumption in relation to breast cancer risk in a cohort of United States women 25-42 years of age. *Cancer Epidemiol Biomarkers Prev.* 1999;8:1017-21.
 56. Zhang Y, Kreger BE, Dorgan JF, Splansky GL, Cupples LA, Ellison RC. Alcohol consumption and risk of breast cancer: the Framingham Study revisited. *Am J Epidemiol.* 1999;149:93-101.
 57. Rohan TE, Jain M, Howe GR, Miller AB. Alcohol consumption and risk of breast cancer: A cohort study. *Cancer Cause Control.* 2000;11:239-47.

58. Feigelson HS, Calle EE, Robertson AS, Wingo PA, Thun MJ. Alcohol consumption increases the risk of fatal breast cancer (United States). *Cancer Causes Control*. 2001;12:895-902.
59. Chen WY, Colditz GA, Rosner B, Hankinson SE, Hunter DJ, Manson JE, et al. Use of postmenopausal hormones, alcohol, and risk for invasive breast cancer. *Ann Intern Med*. 2002;137:798-804.
60. Horn-Ross PL, Hoggatt KJ, West DW, Krone MR, Stewart SL, Anton H, et al. Recent diet and breast cancer risk: the California Teachers Study (USA). *Cancer Causes Control*. 2002;13:407-15.
61. Feigelson HS, Jonas CR, Robertson AS, McCullough ML, Thun MJ, Calle EE. Alcohol, folate, methionine, and risk of incident breast cancer in the American Cancer Society Cancer Prevention Study II Nutrition Cohort. *Cancer Epidemiol Biomarkers Prev*. 2003;12:161-4.
62. Dumeaux V, Lund E, Hjartaker A. Use of oral contraceptives, alcohol, and risk for invasive breast cancer. *Cancer Epidemiol Biomarkers Prev*. 2004;13:1302-7.
63. Horn-Ross PL, Canchola AJ, West DW, Stewart SL, Bernstein L, Deapen D, et al. Patterns of alcohol consumption and breast cancer risk in the California Teachers Study cohort. *Cancer Epidemiol Biomarkers Prev*. 2004;13:405-11.
64. Sellers TA, Grabrick DM, Vierkant RA, Harnack L, Olson JE, Vachon CM, et al. Does folate intake decrease risk of postmenopausal breast cancer among women with a family history? *Cancer Causes Control*. 2004;15:113-20.
65. Suzuki R, Ye W, Rylander-Rudqvist T, Saji S, Colditz GA, Wolk A. Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: A prospective cohort study. *J Nat Cancer Inst*. 2005;97:1601-8.
66. Mellekjaer L, Bigaard J, Tjonneland A, Christensen J, Thomsen B, Johansen C, et al. Body composition and breast cancer in postmenopausal women: a Danish prospective cohort study. *Obesity*. 2006;14:1854-62.
67. Stolzenberg-Solomon RZ, Chang SC, Leitzmann MF, Johnson KA, Johnson C, Buys SS, et al. Folate intake, alcohol use, and postmenopausal breast cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *Am J Clin Nutr*. 2006;83:895-904.
68. Tjonneland A, Christensen J, Olsen A, Stripp C, Thomsen BL, Overvad K, et al.

- Alcohol intake and breast cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). *Cancer Causes Control*. 2007;18:361-73.
69. Zhang SM, Lee IM, Manson JE, Cook NR, Willett WC, Buring JE. Alcohol consumption and breast cancer risk in the Women's Health Study. *Am J Epidemiol*. 2007;165:667-76.
 70. Lew JQ, Freedman ND, Leitzmann MF, Brinton LA, Hoover RN, Hollenbeck AR, et al. Alcohol and risk of breast cancer by histologic type and hormone receptor status in postmenopausal women: the NIH-AARP Diet and Health Study. *Am J Epidemiol*. 2009;170:308-17.
 71. Li CI, Chlebowski RT, Freiberg M, Johnson KC, Kuller L, Lane D, et al. Alcohol consumption and risk of postmenopausal breast cancer by subtype: the women's health initiative observational study. *J Natl Cancer Inst*. 2010;102:1422-31.
 72. Chen WY, Rosner B, Hankinson SE, Colditz GA, Willett WC. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. *JAMA*. 2011;306:1884-90.
 73. Kawai M, Minami Y, Kakizaki M, Kakugawa Y, Nishino Y, Fukao A, et al. Alcohol consumption and breast cancer risk in Japanese women: the Miyagi Cohort study. *Breast Cancer Res Treat*. 2011;128:817-25.
 74. Liu Y, Colditz GA, Rosner B, Berkey CS, Collins LC, Schnitt SJ, et al. Alcohol intake between menarche and first pregnancy: a prospective study of breast cancer risk. *J Natl Cancer Inst*. 2013;105:1571-8.
 75. Falk RT, Maas P, Schairer C, Chatterjee N, Mabie JE, Cunningham C, et al. Alcohol and risk of breast cancer in postmenopausal women: an analysis of etiological heterogeneity by multiple tumor characteristics. *Am J Epidemiol*. 2014;180:705-17.
 76. Park SY, Kolonel LN, Lim U, White KK, Henderson BE, Wilkens LR. Alcohol consumption and breast cancer risk among women from five ethnic groups with light to moderate intakes: the Multiethnic Cohort Study. *Int J Cancer*. 2014;134:1504-10.
 77. Chhim AS, Fassier P, Latino-Martel P, Druesne-Pecollo N, Zelek L, Duverger L, et al. Prospective association between alcohol intake and hormone-dependent cancer risk: modulation by dietary fiber intake. *Am J Clin Nutr*. 2015;102:182-9.
 78. Fagherazzi G, Vilier A, Boutron-Ruault MC, Mesrine S, Clavel-Chapelon F. Alcohol consumption and breast cancer risk subtypes in the E3N-EPIC cohort. *Eur J Cancer*

- Prev. 2015;24:209-14.
79. Shin A, Sandin S, Lof M, Margolis KL, Kim K, Couto E, et al. Alcohol consumption, body mass index and breast cancer risk by hormone receptor status: Women' Lifestyle and Health Study. *BMC Cancer*. 2015;15.
 80. Nitta J, Nojima M, Ohnishi H, Mori M, Wakai K, Suzuki S, et al. Weight Gain and Alcohol Drinking Associations with Breast Cancer Risk in Japanese Postmenopausal Women - Results from the Japan Collaborative Cohort (JACC) Study. *Asian Pac J Cancer Prev*. 2016;17:1437-43.
 81. Gapstur SM, Potter JD, Sellers TA, Kushi LH, Folsom AR. Alcohol consumption and postmenopausal endometrial cancer: results from the Iowa Women's Health Study. *Cancer Causes Control*. 1993;4:323-9.
 82. Terry P, Baron JA, Weiderpass E, Yuen J, Lichtenstein P, Nyren O. Lifestyle and endometrial cancer risk: a cohort study from the Swedish Twin Registry. *Int J Cancer*. 1999;82:38-42.
 83. Loerbroeks A, Schouten LJ, Goldbohm RA, van den Brandt PA. Alcohol consumption, cigarette smoking, and endometrial cancer risk: results from the Netherlands Cohort Study. *Cancer Causes Control*. 2007;18:551-60.
 84. Setiawan VW, Monroe KR, Goodman MT, Kolonel LN, Pike MC, Henderson BE. Alcohol consumption and endometrial cancer risk: the multiethnic cohort. *Int J Cancer*. 2008;122:634-8.
 85. Friberg E, Wolk A. Long-term alcohol consumption and risk of endometrial cancer incidence: a prospective cohort study. *Cancer Epidemiol Biomarkers Prev*. 2009;18:355-8.
 86. Yang HP, Gierach GL, Danforth KN, Sherman ME, Park Y, Wentzensen N, et al. Alcohol and endometrial cancer risk in the NIH-AARP diet and health study. *Int J Cancer*. 2011;128:2953-61.
 87. Je Y, DeVivo I, Giovannucci E. Long-term alcohol intake and risk of endometrial cancer in the Nurses' Health Study, 1980-2010. *Br J Cancer*. 2014;111:186-94.
 88. Chang ET, Canchola AJ, Lee VS, Clarke CA, Purdie DM, Reynolds P, et al. Wine and other alcohol consumption and risk of ovarian cancer in the California Teachers Study cohort. *Cancer Causes Control*. 2007;18:91-103.
 89. Tworoger SS, Gertig DM, Gates MA, Hecht JL, Hankinson SE. Caffeine, alcohol,

- smoking, and the risk of incident epithelial ovarian cancer. *Cancer*. 2008;112:1169-77.
90. Breslow RA, Wideroff L, Graubard BI, Erwin D, Reichman ME, Ziegler RG, et al. Alcohol and prostate cancer in the NHANES I epidemiologic follow-up study. First National Health and Nutrition Examination Survey of the United States. *Ann Epidemiol*. 1999;9:254-61.
 91. Parker AS, Cerhan JR, Putnam SD, Cantor KP, Lynch CF. A cohort study of farming and risk of prostate cancer in Iowa. *Epidemiology*. 1999;10:452-5.
 92. Schuurman AG, Goldbohm RA, van den Brandt PA. A prospective cohort study on consumption of alcoholic beverages in relation to prostate cancer incidence (The Netherlands). *Cancer Causes Control*. 1999;10:597-605.
 93. Ellison LF. Tea and other beverage consumption and prostate cancer risk: a Canadian retrospective cohort study. *Eur J Cancer Prev*. 2000;9:125-30.
 94. Sesso HD, Paffenbarger RS, Jr., Lee IM. Alcohol consumption and risk of prostate cancer: The Harvard Alumni Health Study. *Int J Epidemiol*. 2001;30:749-55.
 95. Albertsen K, Gronbaek M. Does amount or type of alcohol influence the risk of prostate cancer? *Prostate*. 2002;52:297-304.
 96. Platz EA, Leitzmann MF, Rimm EB, Willett WC, Giovannucci E. Alcohol intake, drinking patterns, and risk of prostate cancer in a large prospective cohort study. *Am J Epidemiol*. 2004;159:444-53.
 97. Weinstein SJ, Stolzenberg-Solomon R, Pietinen P, Taylor PR, Virtamo J, Albanes D. Dietary factors of one-carbon metabolism and prostate cancer risk. *Am J Clin Nutr*. 2006;84:929-35.
 98. Velicer CM, Kristal A, White E. Alcohol use and the risk of prostate cancer: results from the VITAL cohort study. *Nutr Cancer*. 2006;56:50-6.
 99. Sutcliffe S, Giovannucci E, Leitzmann MF, Rimm EB, Stampfer MJ, Willett WC, et al. A prospective cohort study of red wine consumption and risk of prostate cancer. *Int J Cancer*. 2007;120:1529-35.
 100. Gong Z, Kristal AR, Schenk JM, Tangen CM, Goodman PJ, Thompson IM. Alcohol consumption, finasteride, and prostate cancer risk: results from the Prostate Cancer Prevention Trial. *Cancer*. 2009;115:3661-9.
 101. Chao C, Haque R, Van Den Eeden SK, Caan BJ, Poon KY, Quinn VP. Red wine consumption and risk of prostate cancer: the California men's health study. *Int J*

- Cancer. 2010;126:171-9.
102. Watters JL, Park Y, Hollenbeck A, Schatzkin A, Albanes D. Alcoholic beverages and prostate cancer in a prospective US cohort study. *Am J Epidemiol.* 2010;172:773-80.
 103. Mahabir S, Leitzmann MF, Virtanen MJ, Virtamo J, Pietinen P, Albanes D, et al. Prospective study of alcohol drinking and renal cell cancer risk in a cohort of Finnish male smokers. *Cancer Epidemiol Biomarkers Prev.* 2005;14:170-5.
 104. Setiawan VW, Stram DO, Nomura AM, Kolonel LN, Henderson BE. Risk factors for renal cell cancer: the multiethnic cohort. *Am J Epidemiol.* 2007;166:932-40.
 105. Schouten LJ, van Dijk BA, Oosterwijk E, van Engeland M, Hulsbergen-van de Kaa CA, Kiemeny LA, et al. Alcohol consumption and mutations or promoter hypermethylation of the von Hippel-Lindau gene in renal cell carcinoma. *Cancer Epidemiol Biomarkers Prev.* 2008;17:3543-50.
 106. Macleod LC, Hotaling JM, Wright JL, Davenport ML, Gore JL, Harper JD, et al. Risk factors for renal cell carcinoma in the vital study. *J Urology.* 2012;187:e32-e3.
 107. Karami S, Daugherty SE, Purdue MP. A prospective study of alcohol consumption and renal cell carcinoma risk. *Int J Cancer.* 2015;137:238-42.
 108. Chyou PH, Nomura AM, Stemmermann GN. A prospective study of diet, smoking, and lower urinary tract cancer. *Ann Epidemiol.* 1993;3:211-6.
 109. Zeegers MP, Volovics A, Dorant E, Goldbohm RA, van den Brandt PA. Alcohol consumption and bladder cancer risk: results from The Netherlands Cohort Study. *Am J Epidemiol.* 2001;153:38-41.
 110. Navarro Silvera SA, Miller AB, Rohan TE. Risk factors for thyroid cancer: a prospective cohort study. *Int J Cancer.* 2005;116:433-8.
 111. Meinhold CL, Park Y, Stolzenberg-Solomon RZ, Hollenbeck AR, Schatzkin A, Berrington de Gonzalez A. Alcohol intake and risk of thyroid cancer in the NIH-AARP Diet and Health Study. *Br J Cancer.* 2009;101:1630-4.
 112. Meinhold CL, Ron E, Schonfeld SJ, Alexander BH, Freedman DM, Linet MS, et al. Nonradiation risk factors for thyroid cancer in the US Radiologic Technologists Study. *Am J Epidemiol.* 2010;171:242-52.
 113. Kabat GC, Kim MY, Wactawski-Wende J, Rohan TE. Smoking and alcohol consumption in relation to risk of thyroid cancer in postmenopausal women. *Cancer Epidemiol.* 2012;36:335-40.

114. Chiu BC, Cerhan JR, Gapstur SM, Sellers TA, Zheng W, Lutz CT, et al. Alcohol consumption and non-Hodgkin lymphoma in a cohort of older women. *Br J Cancer*. 1999;80:1476-82.
115. Lim U, Morton LM, Subar AF, Baris D, Stolzenberg-Solomon R, Leitzmann M, et al. Alcohol, smoking, and body size in relation to incident Hodgkin's and non-Hodgkin's lymphoma risk. *Am J Epidemiol*. 2007;166:697-708.
116. Klatsky AL, Li Y, Baer D, Armstrong MA, Udaltsova N, Friedman GD. Alcohol consumption and risk of hematologic malignancies. *Ann Epidemiol*. 2009;19:746-53.
117. Chang ET, Clarke CA, Canchola AJ, Lu Y, Wang SS, Ursin G, et al. Alcohol consumption over time and risk of lymphoid malignancies in the California Teachers Study cohort. *Am J Epidemiol*. 2010;172:1373-83.
118. Troy JD, Hartge P, Weissfeld JL, Oken MM, Colditz GA, Mechanic LE, et al. Associations between anthropometry, cigarette smoking, alcohol consumption, and non-Hodgkin lymphoma in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *Am J Epidemiol*. 2010;171:1270-81.
119. Gapstur SM, Diver WR, McCullough ML, Teras LR, Thun MJ, Patel AV. Alcohol intake and the incidence of non-hodgkin lymphoid neoplasms in the cancer prevention study II nutrition cohort. *Am J Epidemiol*. 2012;176:60-9.
120. Freedman DM, Sigurdson A, Doody MM, Rao RS, Linet MS. Risk of melanoma in relation to smoking, alcohol intake, and other factors in a large occupational cohort. *Cancer Causes Control*. 2003;14:847-57.
121. Kubo JT, Henderson MT, Desai M, Wactawski-Wende J, Stefanick ML, Tang JY. Alcohol consumption and risk of melanoma and non-melanoma skin cancer in the Women's Health Initiative. *Cancer Causes Control*. 2014;25:1-10.
122. Garfinkel L, Boffetta P, Stellman SD. Alcohol and breast cancer: a cohort study. *Prev Med*. 1988;17:686-93.
123. Kim MK, Ko MJ, Han JT. Alcohol consumption and mortality from all-cause and cancers among 1.34 million Koreans: the results from the Korea national health insurance corporation's health examinee cohort in 2000. *Cancer Causes Control*. 2010;21:2295-302.
124. Boffetta P, Garfinkel L. Alcohol drinking and mortality among men enrolled in an American Cancer Society prospective study. *Epidemiology*. 1990;1:342-8.

125. Sakata K, Hoshiyama Y, Morioka S, Hashimoto T, Takeshita T, Tamakoshi A. Smoking, alcohol drinking and esophageal cancer: findings from the JACC Study. *J Epidemiol.* 2005;15 Suppl 2:S212-9.
126. Shen C, Schooling CM, Chan WM, Xu L, Lee SY, Lam TH. Alcohol intake and death from cancer in a prospective Chinese elderly cohort study in Hong Kong. *J Epidemiol Community Health.* 2013;67:813-20.
127. Camargo CA, Jr., Hennekens CH, Gaziano JM, Glynn RJ, Manson JE, Stampfer MJ. Prospective study of moderate alcohol consumption and mortality in US male physicians. *Arch Intern Med.* 1997;157:79-85.
128. Thun MJ, Peto R, Lopez AD, Monaco JH, Henley SJ, Heath CW, Jr., et al. Alcohol consumption and mortality among middle-aged and elderly U.S. adults. *N Eng J Med.* 1997;337:1705-14.
129. Breslow RA, Chen CM, Graubard BI, Mukamal KJ. Prospective study of alcohol consumption quantity and frequency and cancer-specific mortality in the US population. *Am J Epidemiol.* 2011;174:1044-53.
130. Gaziano JM, Gaziano TA, Glynn RJ, Sesso HD, Ajani UA, Stampfer MJ, et al. Light-to-moderate alcohol consumption and mortality in the Physicians' Health Study enrollment cohort. *J Am Coll Cardiol.* 2000;35:96-105.
131. Gapstur SM, Jacobs EJ, Deka A, McCullough ML, Patel AV, Thun MJ. Association of alcohol intake with pancreatic cancer mortality in never smokers. *Arch Intern Med.* 2011;171:444-51.
132. Yagyu K, Kikuchi S, Obata Y, Lin Y, Ishibashi T, Kurosawa M, et al. Cigarette smoking, alcohol drinking and the risk of gallbladder cancer death: a prospective cohort study in Japan. *Int J Cancer.* 2008;122:924-9.
133. Thun MJ, Hannan LM, DeLancey JO. Alcohol consumption not associated with lung cancer mortality in lifelong nonsmokers. *Cancer Epidemiol Biomarkers Prev.* 2009;18:2269-72.
134. Fuchs CS, Stampfer MJ, Colditz GA, Giovannucci EL, Manson JE, Kawachi I, et al. Alcohol consumption and mortality among women. *N Eng J Med.* 1995;332:1245-50.
135. Jain MG, Ferrenc RG, Rehm JT, Bondy SJ, Rohan TE, Ashley MJ, et al. Alcohol and breast cancer mortality in a cohort study. *Breast Cancer Res Treat.* 2000;64:201-9.



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	3-4
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	6
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	NA
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	7
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6-7
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6-7
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	7
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7-8
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7-8
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	NA
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	7-8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	8



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	9
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	9-10
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	NA
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	10
Synthesis of results	21	Present the main results of the review. If meta-analyses are done, include for each, confidence intervals and measures of consistency.	10-13
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	NA
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	10-13
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	13-17
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	17
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	18
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	19

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2